documents incorporated reference parts ii iii portions registrants annual report shareholders fiscal year annual report parts iii portions registrants proxy statement annual meeting shareholders filed within days close registrants fiscal year proxy statementitem part business general segments business geographic areas raw materials patents trademarks seasonality competition research development environment regulation available information risk factors b unresolved staff comments properties legal proceedings mine safety disclosures executive officers registrant part ii market registrants common equity related stockholder matters issuer purchases equity securities selected financial data managements discussion analysis financial condition results operations quantitative qualitative disclosures market risk financial statements supplementary data changes disagreements accountants accounting financial disclosure controls procedures b information part iii directors executive officers corporate governance executive compensation security ownership certain beneficial owners management related stockholder matters certain relationships related transactions director independence principal accountant fees services part iv exhibits financial statement schedules signatures exhibit index table contents part item business general johnson johnson subsidiaries company approximately employees worldwide engaged research development manufacture sale broad range products health care field johnson johnson holding company operating companies conducting business virtually countries world companys primary focus products related human health wellbeing johnson johnson incorporated state new jersey companys structure based principle decentralized management executive committee johnson johnson principal management group responsible strategic operations allocation resources company committee oversees coordinates activities consumer pharmaceutical medical devices previously referred medical devices diagnostics business segments within strategic parameters provided committee senior management groups us international operating companies responsible strategic plans well daytoday operations companies subsidiary within business segments exceptions managed citizens country located segments business company organized three business segments consumer pharmaceutical medical devices additional information required item incorporated herein reference narrative tabular descriptions segments operating results caption managements discussion analysis results operations financial condition note segments business geographic areas notes consolidated financial statements annual report filed exhibit report consumer consumer segment includes broad range products used baby care oral care skin care overthecounter pharmaceutical womens health wound care markets baby care includes johnsons baby line products oral care includes listerine product line major brands skin care include aveeno clean clear dabao johnsons adult le petite marseillais lubriderm neutrogena roc product lines overthecounter medicines include broad family tylenol acetaminophen products sudafed cold flu allergy products benadryl zyrtec allergy products motrin ib ibuprofen products pepcid line heartburn products major brands womens health outside north america stayfree carefree sanitary pad ob tampon brands wound care brands include bandaid brand adhesive bandages neosporin first aid product lines principal nutritional line splenda calorie sweetener products marketed general public sold retail outlets distributors throughout world pharmaceutical pharmaceutical segment focused five therapeutic areas including immunology eg rheumatoid arthritis inflammatory bowel disease psoriasis pulmonary diseases infectious diseases eg hiv hepatitis respiratory infections tuberculosis vaccines neuroscience eg alzheimer 's disease mood disorders schizophrenia pain oncology eg prostate cancer multiple myeloma hematologic malignancies lung cancer cardiovascular metabolic diseases eg thrombosis diabetes products segment distributed directly retailers wholesalers hospitals health care professionals prescription use key products pharmaceutical segment include remicade infliximab treatment number immunemediated inflammatory diseases simponi golimumab subcutaneous treatment adults moderate severe rheumatoid arthritis active psoriatic arthritis active ankylosing spondylitis moderately active severely active ulcerative colitis simponi aria golimumab intravenous treatment adults moderate severe rheumatoid arthritis stelara ustekinumab treatment adults moderate severe plaque psoriasis active psoriatic arthritis incivo telaprevir treatment hepatitis c olysiosovriadsimeprevir combination treatment chronic hepatitis c adult patients prezista darunavir treatment hivaids edurant rilpivirine treatment hiv concerta methylphenidate hcl extendedrelease tablets cii treatment attention deficit hyperactivity disorder invega paliperidone extendedrelease tablets treatment schizophrenia schizoaffective disorder invega sustennaxeplion paliperidone palmitate treatment schizophrenia schizoaffective disorder adults risperdal consta risperidone longacting injection treatment schizophrenia maintenance treatment bipolar disorder adults velcade bortezomib treatment multiple myeloma zytiga abiraterone acetate treatment metastatic castrationresistant prostate cancer imbruvica ibrutinib oral oncedaily therapy approved use treating certain bcell malignancies blood table contents cancers procrit epoetin alfa sold outside us eprex stimulate red blood cell production xarelto rivaroxaban oral anticoagulant prevention deep vein thrombosis dvt may lead pulmonary embolism pe patients undergoing hip knee replacement surgery reduce risk stroke systemic embolism patients nonvalvular atrial fibrillation treatment dvt pe reduction risk recurrence dvt pe invokana canagliflozin treatment adults type diabetes many products developed collaboration strategic partners licensed companies medical devices medical devices previously referred medical devices diagnostics segment includes broad range products used orthopaedic surgical care specialty surgery cardiovascular care diagnostics diabetes care vision care markets distributed wholesalers hospitals retailers used principally professional fields physicians nurses hospitals clinics include orthopaedic trauma neurological products general surgery biosurgical energy products products treat cardiovascular disease infection prevention products diagnostics products blood glucose monitoring insulin delivery products disposable contact lenses company completed divestiture orthoclinical diagnostics business june geographic areas business johnson johnson conducted operating companies located countries including us conduct business virtually countries throughout world products made sold international business include many described segments business consumer pharmaceutical medical devices however principal markets products methods distribution international business vary country culture products sold international business include developed united states also developed subsidiaries abroad investments activities countries outside us subject higher risks comparable us activities investment commercial climate may influenced financial instability international economies restrictive economic policies political legal system uncertainties raw materials raw materials essential company 's business generally readily available multiple sources exceptions temporary unavailability raw materials would likely material adverse effect financial results company patents company 's subsidiaries made practice obtaining patent protection products processes possible licensed number patents relating products manufacturing processes aggregate believed material importance company operation businesses sales companys largest product remicade infliximab accounted approximately company 's total revenues fiscal accordingly patents related product believed material company two sets patents related remicade infliximab first set patents coowned janssen biotech inc whollyowned subsidiary johnson johnson nyu langone medical center nyu janssen biotech inc exclusive license nyu 's interests patents patents granted united states certain countries european union certain patents extended supplementary patent certificates australiain united states latest patent expires september patent expired canada march certain countries europe patent extended february germany spain united kingdom sweden austria belgium switzerland denmark francegreece italy luxembourg netherlands australia patent expires august united states patent expiring subject reexamination proceedings instituted third party proceedings ongoing second set patents related remicade granted kennedy institute rheumatology united kingdom europe canada australia united states janssen biotech inc licenses exclusive human antitnf antibodies semiexclusive nonhuman antitnf antibodies patents expire outside united states united states validity patents beenchallenged certain claims invalidated others review various patent offices around world also subject litigation canada company expect additional extensions available patents related remicade loss exclusivity likely result reduction sales biosimilar versions remicadeare introduced market table contents legal matters regarding patents related remicade see note legal proceedings notes consolidated financial statements annual report filed exhibit report heading intellectual property pharmaceutical remicaderelated cases addition competing immunology market remicade company currently marketing stelara ustekinumab simponi golimumab simponi aria golimumab next generation immunology products remaining patent lives nine years trademarks companys subsidiaries made practice selling products trademarks obtaining protection trademarks available means trademarks protected registration united states countries products marketed company considers trademarks aggregate material importance operation businesses seasonality worldwide sales reflect significant degree seasonality however spending heavier fourth quarter year quarters reflects increased spending decisions principally advertising research development activity competition product lines company 's subsidiaries compete companies locally globally throughout world competition exists product lines without regard number size competing companies involved competition research internally externally sourced involving development improvement new existing products processes particularly significant development new innovative products important companys success areas business also includes protecting companys portfolio intellectual property competitive environment requires substantial investments continuing research addition development maintenance customer demand companys consumer products involves significant expenditures advertising promotion research development research activities represent significant part companys businesses research development expenditures relate processes discovering testing developing new products improving existing products well demonstrating product efficacy regulatory compliance prior launch company remains committed investing research development aim delivering high quality innovative products worldwide costs research development activities amounted billion billion billion fiscal years respectively major research facilities located united states also belgium brazil canada china france germany india israel japan netherlands singapore switzerland united kingdom environment company subject variety us international environmental protection measures company believes operations comply material respects applicable environmental laws regulations companys compliance requirements past year expected material effect upon capital expenditures cash flows earnings competitive position regulation companys businesses subject varying degrees governmental regulation countries operations conducted general trend toward increasingly stringent regulation us drug device diagnostics cosmetic industries long subject regulation various federal state agencies primarily product safety efficacy manufacturing advertising labeling safety reporting exercise broad regulatory powers us food drug administration fda continues result increases amounts testing documentation required fda clearance new drugs devices corresponding increase expense product introduction similar trends also evident major markets outside us costs human health care continue subject study investigation regulation governmental agencies legislative bodies around world us attention focused drug prices profits programs encourage doctors write prescriptions particular drugs recommend use purchase particular medical devices payers become potent force market place increased attention paid table contents drug medical device pricing appropriate drug medical device utilization quality costs health care generally following us supreme court decision june upholding patient protection affordable care act aca increase pace regulatory issuances us government agencies designated carry extensive requirements aca positive negative impacts us healthcare industry much remaining uncertain various provisions aca ultimately affect industry regulatory agencies whose purview company operates administrative powers may subject actions product withdrawals recalls seizure products civil criminal sanctions cases companys subsidiaries may deem advisable initiate product recalls addition business practices health care industry come increased scrutiny particularly united states government agencies state attorneys general resulting investigations prosecutions carry risk significant civil criminal penalties company relies global supply chains production distribution processes complex subject increasing regulatory requirements may affect sourcing supply pricing materials used company 's products subject lengthy regulatory approvals available information companys main corporate website address wwwjnjcom copies companys quarterly reports form q annual report current reports form k filed furnished us securities exchange commission sec amendments foregoing provided without charge shareholder submitting written request secretary principal executive offices company calling companys sec filings also available companys website wwwinvestorjnjcomgovernancesecfilingscfm soon reasonably practicable electronically filed furnished sec sec filings also available secs website wwwsecgov addition written charters audit committee compensation benefits committee nominating corporate governance committee regulatory compliance government affairs committee science technology sustainability committee board directors companys principles corporate governance policy business conduct employees code business conduct ethics members board directors executive officers corporate governance materials available wwwinvestorjnjcomgovernancematerialscfm company 's website provided without charge shareholder submitting written request provided information companys website deemed part report incorporated filings company makes sec item risk factors company faces number uncertainties risks difficult predict many outside company 's control addition information report companys filings sec investors consider carefully factors set forth exhibit report investors realize known unknown risks uncertainties materialize companys business results operations financial condition could adversely affected item b unresolved staff comments applicable table contents item properties company 's subsidiaries operate manufacturing facilities occupying approximately million square feet floor space manufacturing facilities used industry segments companys business approximately follows square feet segment thousands consumer pharmaceutical medical devices worldwide total within united states eight facilities used consumer segment eight pharmaceutical segment medical devices segment companys manufacturing operations outside united states often conducted facilities serve one business segment divestiture orthoclinical diagnostics business resulted sale eight manufacturing facilities seven united states one europe locations manufacturing facilities major geographic areas world follows square feet geographic area number facilities thousands united states europe western hemisphere excluding us africa asia pacific worldwide total addition manufacturing facilities discussed company maintains numerous office warehouse facilities throughout world research facilities also discussed item business research development company 's subsidiaries generally seek manufacturing facilities although principally nonus locations leased office warehouse facilities often leased company committed maintaining properties good operating condition repair facilities well utilized mcneilppc inc continues operate consent decree signed fda governs certain mcneil consumer healthcare manufacturing operations consent decree consent decree requires mcneilppc remediate facilities operates lancaster pennsylvania fort washington pennsylvania las piedras puerto rico fort washington facility voluntarily shut april remain shut thirdparty current good manufacturing practices cgmp expert certifies operations compliance applicable law fda concurs thirdparty certification many products previously made fort washington transferred manufacturing sites successfully reintroduced market lancaster las piedras facilities continue manufacture distribute drugs thirdparty oversight thirdparty oversight cease fda determined facilities appear compliance applicable law facility operating consent decree subject fiveyear audit period thirdparty cgmp expert facility deemed fda apparent compliance applicable law mcneil successfully completed requirements contained consent decree workplan lancaster las piedras manufacturing sites completed steps required thirdparty certification fort washington plant february thirdparty cgmp expert submitted written certification fda three manufacturing sites timeline completion fda inspection within fda 's discretion discussion legal proceedings related matter found heading government proceedings mcneil consumer healthcare note legal proceedings notes consolidated financial statements annual report filed exhibit report table contents information regarding lease obligations see note rental expense lease commitments notes consolidated financial statements annual report filed exhibit report segment information additions property plant equipment contained note segments business geographic areas notes consolidated financial statements annual report filed exhibit report item legal proceedings following information incorporated herein reference information set forth note legal proceedings notes consolidated financial statements annual report filed exhibit report addition johnson johnson subsidiaries time time party government investigations inspections proceedings relating environmental matters including compliance applicable environmental laws connection routine inspection subsidiary 's manufacturing facility california department toxic substances control alleged violation regulations dealing handling certain wastes fourth quarter subsidiary entered settlement agreement state california agreed perform certain remedial actions pay approximately settle claim item mine safety disclosures applicable executive officers registrant listed executive officers company february family relationships executive officers arrangement understanding executive officer person pursuant executive officer selected annual meeting board directors executive officers elected board hold office one year respective successors elected qualified earlier resignation removal information regard directors company including information alex gorsky incorporated herein reference material captioned item election directors proxy statement name age position dominic j caruso member executive committee vice president finance chief financial officera peter fasolo member executive committee vice president global human resourcesb alex gorsky chairman board directors chairman executive committee chief executive officer sandra e peterson member executive committee group worldwide chairmanc paulus stoffels member executive committee chief scientific officer worldwide chairman pharmaceuticalsd michael h ullmann member executive committee vice president general counsele mr j caruso joined company company acquired centocor inc time acquisition senior vice president finance centocor mr caruso named vice president finance orthomcneil pharmaceutical inc subsidiary company vice president group finance companys medical devices diagnostics group mr caruso named vice president companys group finance organization mr caruso became member executive committee vice president finance chief financial officer b dr p fasolo joined company vice president worldwide human resources cordis corporation subsidiary company named vice president global talent management company left johnson johnson join kohlberg kravis roberts co chief talent officer dr fasolo returned company vice president global human resources became member executive committee c ms e peterson joined company group worldwide chairman member executive committee responsibility consumer group companies consumer medical device businesses vision care diabetes care franchises functions johnson johnson supply chain information table contents technology wellness prevention global strategic design prior joining johnson johnson ms peterson extensive global career healthcare consumer goods consulting recently chairman chief executive officer bayer cropscience ag germany previously serving president chief executive officer bayer medical care president bayer healthcare ag 's diabetes care division joining bayer ms peterson held number leadership roles medco health solutions previously known merckmedco among responsibilities application information technology healthcare systems dr p stoffels joined company acquisition virco tibotec chief executive officer virco chairman tibotec appointed company group chairman global virology led development prezista intelence leading products treatment hiv assumed role company group chairman pharmaceuticals responsibility worldwide research development central nervous system internal medicine franchises dr stoffels appointed global head research development pharmaceuticals became worldwide chairman pharmaceuticals responsibility company 's therapeutic pipeline global research development strategic business development dr stoffels also appointed chief scientific officer responsibility enterprisewide innovation product safety member executive committee e mr h ullmann joined company corporate attorney law department appointed corporate secretary served role time also held various management positions law department named general counsel medical devices diagnostics mr ullmann appointed vice president general counsel member executive committee part ii item market registrants common equity related stockholder matters issuer purchases equity securities february record holders common stock company additional information called item incorporated herein reference material captions managements discussion analysis results operations financial condition liquidity capital resources dividends information common stock market prices note common stock stock option plans stock compensation agreements notes consolidated financial statements shareholder return performance graphs supporting schedules annual report filed exhibit report item security ownership certain beneficial owners management related stockholder matters equity compensation plan information report issuer purchases equity securities july company announced board directors approved share repurchase program authorizing company purchase billion company 's common stock share repurchases take place open market time time based market conditions repurchase program time limit may suspended periods discontinued time following table provides information respect common stock purchases company fiscal fourth quarter common stock purchases open market made part systematic plan meet needs companys compensation programs repurchases also include stockforstock option exercises settled fiscal fourth quarter total number maximum number shares units approximate dollar value total number purchased part shares units may shares avg price publicly announced yet purchased period purchased paid per share plans programs plans programs september october october november november december total fiscal fourth quarter company repurchased aggregate shares johnson johnson common stock openmarket transactions shares purchased pursuant repurchase program publicly announced july shares purchased openmarket transactions part systematic plan meet needs companys compensation programs table contents december aggregate shares purchased total billion since inception repurchase program announced july december maximum number shares may yet purchased plan based closing price johnson johnson common stock new york stock exchange december per share item selected financial data information called item incorporated herein reference summary operations statistical data supporting schedules annual report filed exhibit report item managements discussion analysis financial condition results operations information called item incorporated herein reference narrative tabular material caption managements discussion analysis results operations financial condition annual report filed exhibit report item quantitative qualitative disclosures market risk information called item incorporated herein reference material caption managements discussion analysis results operations financial condition liquidity capital resources financing market risk note summary significant accounting policies financial instruments notes consolidated financial statements annual report filed exhibit report item financial statements supplementary data information called item incorporated herein reference audited consolidated financial statements notes thereto material caption report independent registered public accounting firm annual report filed exhibit report item changes disagreements accountants accounting financial disclosure applicable item controls procedures disclosure controls procedures end period covered report company evaluated effectiveness design operation disclosure controls procedures companys disclosure controls procedures designed ensure information required disclosed company reports files submits exchange act recorded processed summarized reported within time periods specified secs rules forms disclosure controls procedures include without limitation controls procedures designed ensure information required disclosed company reports files submits exchange act accumulated communicated companys management including principal executive principal financial officers persons performing similar functions appropriate allow timely decisions regarding required disclosure alex gorsky chairman chief executive officer dominic j caruso vice president finance chief financial officer reviewed participated evaluation based evaluation messrs gorsky caruso concluded end period covered report companys disclosure controls procedures effective managements report internal control financial reporting information called item incorporated herein reference material caption managements report internal control financial reporting annual report filed exhibit report changes internal control financial reporting fiscal quarter ended december changes companys internal control financial reporting identified connection evaluation required rules exchange act materially affected reasonably likely materially affect companys internal control financial reporting company implementing multiyear enterprisewide initiative integrate simplify standardize processes systems human resources information technology procurement finance functions enhancements support growth companys financial shared service capabilities standardize financial systems initiative response identified deficiency weakness companys internal control financial reporting response table contents initiative company continue align streamline design operation financial control environment item b information applicable part iii item directors executive officers corporate governance information called item incorporated herein reference material captions item election directors stock ownership section compliance section beneficial ownership reporting compliance discussion audit committee caption corporate governance standing board committees proxy statement material caption executive officers registrant part report companys policy business conduct covers employees including chief executive officer chief financial officer controller meets requirements sec rules promulgated section sarbanesoxley act policy business conduct available companys website wwwinvestorjnjcomgovernancepoliciescfm copies available shareholders without charge upon written request secretary companys principal executive offices substantive amendment policy business conduct waiver policy granted chief executive officer chief financial officer controller posted companys website wwwinvestorjnjcomgovernancecfm within five business days retained website least one year addition company adopted code business conduct ethics members board directors executive officers code business conduct ethics members board directors executive officers available companys website wwwinvestorjnjcomgovernancepoliciescfm copies available shareholders without charge upon written request secretary companys principal executive offices substantive amendment code waiver code granted member board directors executive officer posted companys website wwwinvestorjnjcomgovernancecfm within five business days retained website least one year item executive compensation information called item incorporated herein reference material captions item election directors director compensation compensation committee report compensation discussion analysis executive compensation tables proxy statement material incorporated herein reference material caption compensation committee report proxy statement shall deemed furnished filed report shall deemed incorporated reference filing securities act amended securities exchange act amended result furnishing except extent registrant specifically incorporates reference item security ownership certain beneficial owners management related stockholder matters additional information called item incorporated herein reference material captions stock ownership section compliance proxy statement note common stock stock option plans stock compensation agreements notes consolidated financial statements annual report filed exhibit report table contents equity compensation plan information following table provides certain information december concerning shares companys common stock may issued existing equity compensation plans number securities issued upon weighted average number securities exercise exercise price remaining available outstanding outstanding future issuance equity plan category options rights options rights compensation plans equity compensation plans approved security holders equity compensation plans approved security holders total included category following equity compensation plans approved companys shareholders stock option plan longterm incentive plan longterm incentive plan column excludes shares reflected column number securities issued upon exercise outstanding options rights longterm incentive plan expired april options restricted shares granted subsequent date longterm incentive plan item certain relationships related transactions director independence information called item incorporated herein reference material captions transactions related persons corporate governance director independence proxy statement item principal accountant fees services information called item incorporated herein reference material caption ratification appointment independent registered public accounting firm proxy statement table contents part iv item exhibits financial statement schedules following documents filed part report financial statements following audited consolidated financial statements notes thereto material caption report independent registered public accounting firm annual report incorporated herein reference filed exhibit report consolidated balance sheets end fiscal years consolidated statements earnings fiscal years consolidated statements comprehensive income fiscal years consolidated statements equity fiscal years consolidated statements cash flows fiscal years notes consolidated financial statements report independent registered public accounting firm schedules listed omitted required applicable exhibits required filed item l regulation sk information called item incorporated herein reference exhibit index report table contents signatures pursuant requirements section securities exchange act registrant duly caused report signed behalf undersigned thereunto duly authorized date february johnson johnson registrant gorsky gorsky chairman board directors chief executive officer pursuant requirements securities exchange act report signed following persons behalf registrant capacities dates indicated signature title date gorsky chairman board directors february gorsky chief executive officer director principal executive officer j caruso chief financial officer principal financial officer february j caruso j cosgrove controller principal accounting officer february j cosgrove coleman director february coleman j g cullen director february j g cullen davis director february davis e l davis director february e l davis table contents signature title date l lindquist director february l lindquist b mcclellan director february b mcclellan mulcahy director february mulcahy l f mullin director february l f mullin w perez director february w perez c prince director february c prince e washington director february e washington r williams director february r williams table contents exhibit index reg sk exhibit table description item exhibit ia restated certificate incorporation effective april incorporated herein reference exhibit registrants annual report year ended december ib certificate amendment restated certificate incorporation company effective may incorporated herein reference exhibit registrants annual report year ended january ic certificate amendment restated certificate incorporation company effective may incorporated herein reference exhibit aiii registrants annual report year ended december id certificate amendment restated certificate incorporation company effective may incorporated herein reference exhibit registrants form q quarterly report quarter ended july ie certificate amendment restated certificate incorporation company effective april incorporated herein reference exhibit registrants form q quarterly report quarter ended april ii bylaws company amended effective april incorporated herein reference exhibit registrants form k current report filed april upon request securities exchange commission registrant furnish copy instruments defining rights holders longterm debt registrant stock option plan amended incorporated herein reference exhibit b registrant 's annual report year ended january b longterm incentive plan incorporated herein reference exhibit registrants registration statement filed commission may file c form restricted shares nonemployee directors longterm incentive plan incorporated herein reference exhibit registrants form k current report filed august form stock option certificate restricted share unit certificate performance share unit certificate longterm incentive plan incorporated herein reference exhibits registrants form k current report filed january e longterm incentive plan incorporated herein reference appendix registrants proxy statement filed commission march f form stock option certificate restricted share unit certificate performance share unit certificate longterm incentive plan incorporated herein reference exhibits registrants form q quarterly report filed may g executive incentive plan amended incorporated herein reference exhibit f registrants annual report year ended december h domestic deferred compensation certificate extra compensation plan incorporated herein reference exhibit g registrants annual report year ended december amendments certificate extra compensation plan effective january incorporated herein reference exhibit j registrants annual report year ended december j certificates longterm performance plan incorporated herein reference exhibit registrants form q quarterly report quarter ended september k amended restated deferred fee plan directors incorporated herein reference exhibit k registrant 's annual report year ended january l executive income deferral plan amended restated incorporated herein reference exhibit registrants form q quarterly report quarter ended september table contents reg sk exhibit table description item exhibit excess savings plan incorporated herein reference exhibit j registrants form k annual report year ended december n amendments johnson johnson excess savings plan effective january incorporated herein reference exhibit p registrants annual report year ended december excess benefit plan supplemental retirement plan incorporated herein reference exhibit h registrants form k annual report year ended january p amendments excess benefit plan johnson johnson affiliated companies effective january incorporated herein reference exhibit r registrants annual report year ended december q amendment excess benefit plan johnson johnson affiliated companies effective january filed document r executive life plan agreement incorporated herein reference exhibit registrants annual report year ended january johnson johnson retirement savings plan johnson johnson savings plan union represented employees johnson johnson savings plan incorporated herein reference exhibits registrant 's form filed commission may employment agreement dr paulus stoffels incorporated herein reference exhibit registrants form q quarterly report quarter ended september u summary employment arrangements sandra e peterson incorporated herein reference exhibit registrant 's annual report year ended december v severance pay plan johnson johnson us affiliated companies amended restated october incorporated herein reference exhibit registrant 's form q quarterly report quarter ended september statement computation ratio earnings fixed charges filed document following sections annual report shareholders fiscal year incorporated reference report deemed filed management 's discussion analysis results operations financial condition audited consolidated financial statements supporting schedules summary operations statistical data supporting schedules shareholder return performance graphs filed document subsidiaries filed document consent independent registered public accounting firm filed document certification chief executive officer pursuant section sarbanesoxley act filed document b certification chief financial officer pursuant section sarbanesoxley act filed document certification chief executive officer pursuant section sarbanesoxley act furnished document b certification chief financial officer pursuant section sarbanesoxley act furnished document cautionary statement pursuant private securities litigation reform act safe harbor forwardlooking statements filed document xbrl extensible business reporting language following materials johnson johnsons annual report form k fiscal yearended december formatted extensive business reporting language xbrl consolidated balance sheets ii consolidated statements earnings iii consolidated statements comprehensive income iv consolidated statements equity v consolidated statements cash flows vi notes consolidated financial statements management contract compensatory plan copy exhibits listed provided without charge shareholder submitting written request specifying desired exhibits secretary principal executive offices company exhibit q certification amendments excess benefit plan johnson johnson affiliated companies effective january excess benefit plan johnson johnson affiliated companies plan hereby amended incorporate amendments attached hereto date december podlogar sm podlogar vice president global total rewards performance member pension benefits committeeamendment excess benefit plan johnson johnson affiliated companies effective january excess benefit plan johnson johnson affiliated companies plan amended insert following new rvp addendum end plan rvp addendum excess rvp benefit effective january consolidated retirement plan johnson johnson qualified plan amended adopt new benefit formula called retirement value rvp formula notwithstanding provision plan benefit paid plan respect benefits accrued rvp formula shall excess rvp benefit described rvp addendum respect rvp benefits provisions rvp addendum shall apply lieu article ii benefits modified respect time form payment addendum provisions plan including provisions addendum required comply section code shall continue apply amount excess rvp benefit participants excess rvp benefit plan shall equal excess lumpsum amount calculated rvp formula set forth article qualified plan determined payment date set forth paragraph computed without regard limitations imposed sections internal revenue code amended code b actual lumpsum amount payable rvp formula set forth article qualified plan date time form payment excess rvp benefit except provided event death participants excess rvp benefit shall paid lump sum first day seventh month participants separation service within meaning treasury regulations section ah applicable rules section code death participant dies payment date prescribed paragraph excess rvp benefit calculated applying formula paragraph death benefit payable qualified plan shall paid beneficiary lump sum first day month participants deathexhibit johnson johnson subsidiaries statement computation ratio earnings fixed charges dollars millions fiscal year ended december december december january january determination earnings earnings provision taxes income fixed charges less capitalized interest total earnings defined fixed charges estimated interest portion rent expense interest expense capitalization interest total fixed charges ratio earnings fixed charges ratio earnings fixed charges computed dividing sum earnings provision taxes income fixed charges fixed charges fixed charges represent interest expense interest capitalized amortization debt discount appropriate interest factor operating leasestable contents managements discussion analysis results operations financial condition organization business segments results operations analysis sales business segments analysis consolidated earnings provision taxes income liquidity capital resources information cautionary factors may affect future results audited consolidated financial statements consolidated balance sheets consolidated statements earnings consolidated statements comprehensive income consolidated statements equity consolidated statements cash flows notes consolidated financial statements report independent registered public accounting firm managements report internal control financial reporting supporting schedules summary operations statistical data shareholder return performance graphs johnson johnson annual report managements discussion analysis results operations financial condition organization business segments description company business segments johnson johnson subsidiaries company approximately employees worldwide engaged research development manufacture sale broad range products health care field company conducts business virtually countries world primary focus products related human health wellbeing company organized three business segments consumer pharmaceutical medical devices previously referred medical devices diagnostics consumer segment includes broad range products used baby care oral care skin care overthecounter pharmaceutical womens health wound care markets products marketed general public sold retail outlets distributors throughout world pharmaceutical segment focused five therapeutic areas including immunology infectious diseases neuroscience oncology cardiovascular metabolic diseases products segment distributed directly retailers wholesalers hospitals health care professionals prescription use medical devices segment includes broad range products used orthopaedic surgical care specialty surgery cardiovascular care diagnostics diabetes care vision care markets distributed wholesalers hospitals retailers used principally professional fields physicians nurses hospitals clinics companys structure based upon principle decentralized management executive committee johnson johnson principal management group responsible strategic operations allocation resources company committee oversees coordinates activities consumer pharmaceutical medical devices business segments product lines company competes companies locally globally throughout world competition exists product lines without regard number size competing companies involved competition research involving development improvement new existing products processes particularly significant development new innovative products important companys success areas business also includes protecting companys portfolio intellectual property competitive environment requires substantial investments continuing research addition development maintenance customer demand companys consumer products involves significant expenditures advertising promotion managements objectives company manages within strategic framework credo foundation company believes strategic operating principles broadly based human health care managing business long term decentralized management approach commitment people values required successfully meet demands rapidly evolving markets compete end management focused growth drivers creating value innovation expanding global reach local focus excellence execution leading purpose company engages areas human health care opportunity make meaningful difference committed creating value developing broadly accessible high quality innovative products services new products introduced within past five years accounted approximately sales billion sales invested research development reflecting managements commitment delivering new differentiated products services meet evolving health care needs sustain companys longterm growth diverse businesses operating companies located countries key drivers companys success maintaining companys decentralized management approach time leveraging extensive resources enterprise uniquely positions company innovate execute reach markets globally focusing needs challenges local markets order remain leader health care company strives maintain purposedriven organization committed developing global business leaders achieve growth objectives businesses managed longterm order sustain market leadership positions enable growth provides enduring source value shareholders credo unifies johnson johnson employees achieving objectives provides common set values serve foundation companys responsibilities customers employees communities shareholders company believes basic principles growth drivers along overall mission improving quality life people across globe enable johnson johnson continue leader health care industry johnson johnson annual report results operations analysis consolidated sales worldwide sales increased billion compared increases sales changes consisted following sales increasedecrease due volume price currency total sales company 's hepatitis c products olysiosovriad simeprevir incivo telaprevir positive impact divestiture orthoclinical diagnostics business negative impact worldwide operational growth acquisition synthes inc net related divestiture increased worldwide operational growth respectively sales us companies billion billion billion represents increases sales international companies billion billion billion represents increases fiveyear compound annual growth rates worldwide us international sales respectively tenyear compound annual growth rates worldwide us international sales respectively sales europe achieved growth compared prior year including operational growth partially offset negative currency impact sales western hemisphere excluding us experienced decline compared prior year including operational growth offset negative currency impact sales asiapacific africa region achieved growth compared prior year including operational growth negative currency impact company one wholesaler distributing products three segments represented approximately total consolidated revenues company customer represented total consolidated revenues us health care reform provisions patient protection affordable care act health care education reconciliation act beginning company began paying tax deductible excise tax imposed sale certain medical devices fullyear impact excise tax approximately million million july internal revenue service issued final regulations branded prescription drug fee annual nontax deductible fee imposed entities engaged business manufacturing importing branded prescription drugs covered entities enacted section patient protection affordable care act final regulations accelerated expense recognition criteria fee obligation one year year fee paid year sales used calculate fee occur change impacted covered entities resulted need entities record additional expense fee would otherwise expensed paid company accrued additional million fiscal third quarter due change fee associated accelerated expense paid scheduled therefore cash impact johnson johnson annual report analysis sales business segments consumer segment consumer segment sales billion decrease included operational growth offset negative currency impact us consumer segment sales billion decrease international sales billion decrease included operational growth offset negative currency impact major consumer franchise sales change dollars millions vs vs otc skin care baby care oral care wound careother womens health total consumer sales overthecounter otc franchise achieved sales billion increase strong us sales growth driven analgesics upper respiratory products primarily due continued progress returning supply products marketplace mcneilppc inc continues operate consent decree signed us food drug administration fda governs certain mcneil consumer healthcare manufacturing operations consent decree consent decree requires mcneilppc remediate facilities operates lancaster pennsylvania fort washington pennsylvania las piedras puerto rico fort washington facility voluntarily shut april however many products previously made fort washington transferred manufacturing sites successfully reintroduced market lancaster las piedras facilities continue manufacture distribute drugs thirdparty oversight thirdparty oversight cease fda determined facilities appear compliance applicable law february thirdparty overseer submitted written certification fda three manufacturing sites timeline completion fda inspection within fdas discretion skin care franchise achieved sales billion increase compared prior year primarily due strong results aveeno neutrogena dabao product lines baby care franchise sales billion decrease sales growth latin america asia pacific offset impact negative currency regions outside us oral care franchise sales billion increase compared prior year growth driven increased sales listerine productsas result new product launches successful marketing campaigns wound careother franchise sales billion decrease primarily due lower sales nutritionals outside us womens health franchise sales billion decrease primarily due divestiture women 's sanitary protection products us canada caribbean completed fiscal fourth quarter consumer segment sales billion increase included operational growth negative currency impact us consumer segment sales billion increase international sales billion increase included operational growth negative currency impact johnson johnson annual report pharmaceutical segment pharmaceutical segment achieved sales billion representing increase prior year strong operational growth negative currency impact us sales billion increase international sales billion increase included operational growth negative currency impact pharmaceutical segment sales included positive adjustment previous estimates managed medicaid rebates negatively impacted pharmaceutical operational sales growth compared prior year sales company 's hepatitis c products olysiosovriad simeprevir incivo telaprevir positive impact operational growth pharmaceutical segment major pharmaceutical therapeutic area sales change vs vs dollars millions total immunology remicade simponisimponi aria stelara immunology total infectious diseases edurant incivo olysiosovriad prezista infectious diseases total neuroscience concertamethylphenidate invega invega sustennaxeplion risperdal consta neuroscience total oncology velcade zytiga oncology total procriteprex xarelto total pharmaceutical sales prior year amounts reclassified conform current year presentation percentage greater immunology products achieved sales billion representing increase compared prior year increased sales stelara ustekinumab simponisimponiaria golimumab primarily due market growth market share gains remicade infliximab growth primarily due market growth patents remicade certain countries europe germany spain united kingdom sweden austria belgium switzerland denmark france greece italy luxembourg netherlands expire february loss exclusivity likely result reduction sales biosimilar versions introduced market see note consolidated financial statements legal matters regarding remicade patents infectious disease products achieved sales billion representing increase compared prior year major contributors growth launch olysiosovriad simeprevir prezista darunavir due market growth sales edurant rilpivirine partially offset lower sales incivo telaprevir johnson johnson annual report due competitive pressures lower sales vaccine products approval competitive products olysiosovriad simeprevir negative impact fourth quarter expected continue significant negative impact future sales olysiosovriad simeprevir neuroscience products sales billion decline compared prior year strong sales invega sustennaxeplion paliperidone palmitate invega paliperidone palmitate partially offset lower sales risperdal consta additionallya decline sales concertamethylphenidate topamax topiramate due continued generic competition oncology products achieved sales billion representing increase compared prior yearmajor contributors growth strong sales zytigaabiraterone acetate well recent launch imbruvica ibrutinib sales growth velcade bortezomib offset negative currency pharmaceutical sales billion increase compared prior year strong sales xarelto rivaroxaban invokanainvokamet canagliflozin partially offset lower sales aciphexpariet rabeprazole sodium procriteprex epoetin alfa company received several regulatory approvals including us food drug administration fda granted approval imbruvica ibrutinib capsules jointly developed commercialized pharmacyclics inc treatment patients chronic lymphocytic leukemia cll received least one prior therapy european commission ec granted conditional approval sirturo bedaquiline european union use part appropriate combination regimen pulmonary multidrug resistant tuberculosis adult patients fda ec granted approval sylvant siltuximab treatment patients multicentric castlemans disease human immunodeficiency virus negative human herpesvirus negative ec granted approval vokanamet canagliflozinmetformin hcl fixeddose therapy combining canagliflozin immediate release metformin hydrochloride single tablet treatment adults type diabetes olysio simeprevir treatment adult patients genotype chronic hepatitis c invega paliperidone er extend adult indication schizophrenia include adolescents aged years older fda granted approval third indication imbruvica ibrutinib treatment patients cll genetic mutation p deletion del p also granted imbruvica ibrutinib full approval treatment patients cll received least one prior therapy fda granted approval invokamettm canagliflozinmetformin hcl treatment adults type diabetes ec approved imbruvica ibrutinib treatment adult patients relapsed refractory mantle cell lymphoma adult patients chronic lymphocytic leukemia received least one prior therapy firstline presence p deletion tp mutation patients unsuitable chemoimmunotherapy ec also approved rezolsta darunavircobicistat combination antiretroviral medicinal products treatment human immunodeficiency virus infection adults aged years older company submitted several new drug applications ndas fda including nda seeking approval oncedaily fixeddose antiretroviral combination tablet containing darunavir protease inhibitor developed janssen rd ireland marketed prezista us cobicistat investigational pharmacokinetic enhancer boosting agent developed gilead sciences inc use combination human immunodeficiency virus medicines nda threemonth atypical antipsychotic paliperidone palmitate treatment schizophrenia adults nda yondelis trabectedin treatment patients advanced soft tissue sarcoma including liposarcoma leiomyosarcoma subtypes received prior chemotherapy including anthracycline addition supplemental new drug application snda approved fda olysio combination nucleotide analog nsb polymerase inhibitor sofosbuvir developed gilead sciences inc treatment chronic hepatitis c additional sndas also submitted fda olysio treatment adult patients genotype chronic hepatitis c patients coinfected hiv oncemonthly atypical longacting antipsychotic invega sustenna paliperidone palmitate approved treat schizoaffective disorder either monotherapy adjunctive therapy type ii variation application submitted european medicines agency ema additional indication imbruvica ibrutinib treatment patients waldenstrms macroglobulinemia rare type bcell lymphoma marketing authorization application submitted european medicines agency expand label velcade bortezomib include use combination rituximab cyclophosphamide doxorubicin prednisone treatment adult patients previously untreated mantle cell lymphoma pharmaceutical segment sales billion representing increase prior year strong operational growth negative currency impact us sales billion increase international sales billion increase included operational growth negative currency impact pharmaceutical segment operational growth impacted due positive adjustment previous estimates managed medicaid rebates medical devices segment medical devices segment sales billion decrease included operational decline negative currency impact us sales billion decrease compared johnson johnson annual report prior year international sales billion decline compared prior year operational growth offset negative currency impact divestiture orthoclinical diagnostics business negative impact operational growth medical devices segment major medical devices franchise sales change dollars millions vs vs orthopaedics surgical care specialty surgeryother vision care cardiovascular care diabetes care diagnostics total medical devices sales previously referred medical devices diagnostics prior year amounts reclassified conform current year presentation infection prevention included specialty surgeryother orthopaedics franchise achieved sales billion increase prior year growth primarily driven sales trauma sports medicine knee hip products growth negatively impacted continued pricing pressures surgical care franchise sales billion decrease prior year us pricing pressure lower sales women 's health urology products due company 's decision exit certain women 's health products impact negative currency partially offset worldwide sales growth sutures success echelon flex powered endopath stapler outside us specialty surgeryother franchise sales billion increase prior year contributors growth strong sales biosurgical products sales energy products outside us mentor products due new product launches market growth vision care franchise sales billion decrease prior year decline primarily due increased competition pricing pressures us asia pacific region partially offset sales growth europe cardiovascular care franchise achieved sales billion increase prior year increased sales driven strong growth biosense webster products regions diabetes care franchise sales billion decrease versus prior year us lower prices partially offset volume growth diagnostics franchise sales billion decline versus prior year decline due divestiture ortho clinical diagnostics business diagnostics franchise carlyle group june medical devices segment sales billion representing increase prior year operational growth negative currency impact us sales billion increase compared prior year international sales billion increase prior year operational growth negative currency impact acquisition synthes inc net related trauma business divestiture increased total sales growth operational growth medical devices segment respectively johnson johnson annual report analysis consolidated earnings provision taxes income consolidated earnings provision taxes income increased billion compared billion increase earnings provision taxes income favorable due strong sales volume growth particularly sales olysiosovriad simeprevir positive mix higher sales higher margin products pharmaceutical business divestitures lower margin businesses cost reduction efforts across many businesses additionally included higher net gains divestitures billion primarily divestiture orthoclinical diagnostics business lower litigation expense billion lower inprocess research development costs billion lower expenses billion related depuy asr hip program compared fiscal year partially offset inclusion additional year branded prescription drug fee billion billion higher synthes integrationtransaction costs fiscal year included net gain billion equity investment transactions primarily sale elan american depositary shares consolidated earnings provision taxes income increased billion billion compared billion increase earnings provision taxes income favorable due increased gross profit billion resulting higher sales higher margin products cost containment initiatives billion net gain equity investment transactions primarily sale elan american depositary shares partially offset higher litigation expenses billion higher expenses billion related depuy asr hip program compared fiscal year included billion higher writedowns intangible assets inprocess research development higher costs billion related synthes acquisition partially offset higher gains billion related divestitures percent sales consolidated earnings provision taxes income versus cost products sold selling marketing administrative expenses cost products sold selling marketing administrative expenses percent sales follows sales cost products sold percent point decreaseincrease prior year selling marketing administrative expenses percent point decreaseincrease prior year cost products sold percent sales decreased compared prior year primarily result ofpositive mix higher sales higher margin products pharmaceutical business divestitures lower margin businesses cost improvements across many businesses partially offset pricing impact negative transactional currency addition included inventory stepup charge billion related synthes acquisition intangible asset amortization expense included cost products sold billion decrease percent sales selling marketing administrative expenses compared prior year primarily due leveraged costs resulting growth pharmaceutical business particularly sales olysiosovriad simeprevir cost containment initiatives across many businesses partially offset inclusion additional year branded prescription drug fee million fiscal third quarter cost products sold percent sales decreased compared prior year primarily result positive mix resulting higher sales higher margin products lower costs associated strong volume growth pharmaceutical business cost reduction efforts across many businesses decrease partially offset incremental intangible asset amortization expense primarily related synthes medical device excise tax increased amortization expense result royalty buyout agreement vertex incivo intangible asset amortization expense billion billion respectively additionally included billion higher amortization inventory stepup charge related synthes inc acquisition decrease percent sales selling marketing administrative expenses compared prior year primarily due cost containment initiatives across many businesses johnson johnson annual report research development expense research development expense segment business follows dollars millions amount sales amount sales amount sales consumer pharmaceutical medical devices total research development expense percent increasedecrease prior year percent segment sales research development activities represent significant part company 's business expenditures relate processes discovering testing developing new products improving existing products well ensuring product efficacy regulatory compliance prior launch company remains committed investing research development aim delivering high quality innovative products worldwide costs research development activities increased compared reduction percent sales primarily due strong sales growth pharmaceutical business research spending pharmaceutical segment increased absolute dollars billion compared billion primarily due higher levels spending advance company 's pharmaceutical pipeline worldwide costs research development activities increased compared increase pharmaceutical segment primarily due higher levels spending advance company 's pharmaceutical pipeline inprocess research development iprd company recorded charges billion impairment various iprd projects related respivert crucell mentor synthes delay discontinuation certain development projects company recorded charges billion primarily impairment various iprd projects related crucell corimmun acclarent delay discontinuation certain development projects company recorded charges billion included billion impairment iprd related discontinuation phase iii clinical development bapineuzumab iv partial impairment iprd related crucell vaccine business amount billion billion impairment iprd related discontinuation phase iii clinical development bapineuzumab iv billion attributable noncontrolling interest charges relate development projects discontinued delayed income expense net income expense net includes royalty income gains losses related sale writedown certain investments equity securities held johnson johnson development corporation gains losses divestitures currency gains losses litigation accruals settlements change income expense net fiscal year favorable change billion compared prior year fiscal year included higher net gains divestitures billion primarily divestiture ortho clinical diagnostics business lower litigation expense billion lower costs billion related depuy asr hip program compared partially offset higher synthes integrationtransaction costs billion higher intangible asset writedowns billion primarily related incivo telaprevir additionally fiscal year included higher net gain billion compared equity investment transactions primarily sale elan american depositary shares change income expense net fiscal year unfavorable change billion compared prior year fiscal year included net gain billion equity investment transactions primarily sale elan american depositary shares offset higher litigation expenses billion higher expenses billion related depuy asr hip program higher currency losses billion fiscal year included higher writedowns intangible assets billion primarily related crucell vaccine business higher costs billion related synthes acquisition additionally included higher gains billion related divestitures interest income expense interest income comparable prior year higher balance cash cash equivalents marketable securities offset lower interest rates cash cash equivalents marketable securities totaled billion end averaged billion compared billion average cash balance increase yearend cash balance primarily due cash generated operating activities interest expense increased million compared due higher average debt balance average debt balance billion versus billion total debt balance end billion compared billion end higher debt balance approximately billion due increased borrowings november company increased borrowings capitalizing favorable terms capital markets proceeds borrowings used general corporate purposes johnson johnson annual report interest income increased million compared prior year cash cash equivalents marketable securities totaled billion end averaged billion compared billion average cash balance increase year end cash balance due cash generated operating activities interest expense decreased million compared due lower average debt balance average debt balance billion versus billion total debt balance end billion compared billion end higher debt balance approximately billion due increased borrowings december company increased borrowings capitalizing favorable terms capital markets proceeds borrowings used general corporate purposes segment pretax profit pretax profits segment business follows percent segment sales dollars millions consumer pharmaceutical medical devices total less expenses allocated segments earnings provision taxes income see note consolidated financial statements details amounts allocated segments include interest income expense noncontrolling interests general corporate income expense consumer segment consumer segment pretax profit percent sales flat prior year consumer segment pretax profit percent sales versus favorable pretax profit versus primarily due gain million sale intangible assets well cost containment initiatives included intangible asset writedowns billion addition included higher gains divestitures billion pharmaceutical segment pharmaceutical segment pretax profit percent sales versus favorable pretax profit attributable strong sales volume growth particularly sales olysiosovriad simeprevir positive sales mix higher margin products cost containment initiatives realized selling marketing administrative expenses partially offset billion additional year branded prescription drug fee billion intangible asset writedown related incivo telaprevir additionally included net gain billion equity investment transactions primarily sale elan american depositary shares positive adjustment billion previous estimates managed medicaid rebates partially offset higher writedowns billion impairment iprd compared pharmaceutical segment pretax profit percent sales versus favorable pretax profit attributable positive sales mix higher margin products lower costs associated strong volume growth net gain billion equity investment transactions primarily sale elan american depositary shares positive adjustment billion previous estimates managed medicaid rebates cost containment initiatives partially offset increased amortization expense result royalty buyout agreement vertex incivoadditionally included higher net litigation expense billion higher writedowns intangible assets inprocess research development billion partially offset higher gains divestitures billion medical devices segment medical devices segment pretax profit percent sales versus favorable pretax profit attributable net gain billion divestiture orthoclinical diagnostics business lower litigation expense billion compared medical devices segment pretax profit percent sales versus medical devices segment pretax profit unfavorably impacted higher costs billion litigation expense billion related depuy asr hip program well medical device excise tax compared addition included higher gains billion divestitures partially offset higher writedowns intangible assets inprocess research development billion higher costs billion related synthes acquisition provision taxes income worldwide effective income tax rate increase effective tax rate compared attributable following divestiture johnson johnson annual report orthoclinical diagnostics business approximate effective tax rate litigation accruals low tax rates mix earnings higher tax jurisdictions primarily us accrual additional year branded prescription drug fee tax deductible additional us tax expense related planned increase dividends current year foreign earnings compared prior year increases effective tax rate partially offset tax benefit billion associated conor medsystems divestiture effective tax rate reduced tax benefit associated writeoff assets tax purposes associated scios inc inclusion benefit research development tax credit controlled foreign corporation lookthrough provisions provisions enacted law january retroactive january effective tax rate also reduced company adjusted unrecognized tax benefits result federal appeals courts decision omj pharmaceuticals incs litigation regarding credits former section internal revenue code see note consolidated financial statements additional information ii settlement substantially issues related companys us internal revenue service audit tax years noncontrolling interest charge billion recorded impairment iprd related discontinuation phase iii clinical development bapineuzumab iv billion impairment billion attributable noncontrolling interest liquidity capital resources liquidity cash flows cash cash equivalents billion end compared billion end primary sources uses cash contributed billion decrease versus prior year approximately billion cash generated operating activities offset billion net cash used investing activities billion net cash used financing activities see note consolidated financial statements additional details cash addition company billion marketable securities end billion end cash flow operations billion result billion net earnings billion noncash charges adjustments depreciation amortization stockbased compensation asset writedowns venezuela adjustments billion related deferred taxes accounts payable accrued liabilities current noncurrent assets cash flow operations reduced billion related current noncurrent liabilities inventories accounts receivable net gains sale assetsbusinesses investing activities use billion primarily net purchases investments marketable securities billion additions property plant equipment billion acquisitions net cash acquired billion primarily intangibles billion partially offset billion proceeds disposal assetsbusinesses financing activities use billion primarily dividends shareholders billion billion repurchase common stock financing activities also included source billion net proceeds short longterm debt billion net proceeds stock options exercised associated tax benefits july company announced board directors approved share repurchase program authorizing company purchase billion company 's shares common stock december billion repurchased program share repurchases take place open market time time based market conditions repurchase program time limit may suspended periods discontinued time shares acquired available general corporate purposes company intends finance share repurchase program available cash company continued access liquidity commercial paper market additional details borrowings see note consolidated financial statements company anticipates operating cash flows existing credit facilities access commercial paper markets provide sufficient resources fund operating needs concentration credit risk global concentration credit risk respect trade accounts receivables continues limited due large number customers globally adherence internal credit policies credit limits economic challenges italy spain greece portugal southern european region impacted certain payment patterns historically longer experienced us international markets total net trade accounts receivable balance southern european region approximately billion december billion december approximately billion december approximately billion december southern european region net trade accounts receivable balance related company 's consumer vision care diabetes care businesses well certain pharmaceutical medical devices customers line historical collection patterns remaining balance net trade accounts receivable southern european region negatively impacted timing payments certain government owned supported health care customers well certain distributors johnson johnson annual report pharmaceutical medical devices local affiliates total net trade accounts receivable balance customers approximately billion december billion december company continues receive payments customers cases late payment premiums customers payment expected periods time longer one year revenue trade receivables discounted estimated period time collection allowances doubtful accounts increased customers immaterial date company continue work closely customers payment plans monitor economic situation take appropriate actions necessary financing market risk company uses financial instruments manage impact foreign exchange rate changes cash flows accordingly company enters forward foreign exchange contracts protect value certain foreign currency assets liabilities hedge future foreign currency transactions primarily related product costs gains losses contracts offset gains losses underlying transactions appreciation us dollar december market rates would increase unrealized value companys forward contracts million conversely depreciation us dollar december market rates would decrease unrealized value companys forward contracts million either scenario gain loss forward contract would offset gain loss underlying transaction therefore would impact future anticipated earnings cash flows company hedges exposure fluctuations currency exchange rates effect certain assets liabilities foreign currency entering currency swap contracts change spread us foreign interest rates companys interest rate sensitive financial instruments would either increase decrease unrealized value companys swap contracts approximately million either scenario maturity gain loss swap contract would offset gain loss underlying transaction therefore would impact future anticipated cash flows company enter financial instruments trading speculative purposes company policy entering contracts parties least equivalent credit rating counterparties contracts major financial institutions significant concentration exposure one counterparty management believes risk loss remote company access substantial sources funds numerous banks worldwide september company secured new day credit facility total credit available company approximates billion expires september interest charged borrowings credit line agreement based either bids provided banks prime rate london interbank offered rates libor plus applicable margins commitment fees agreement material total borrowings end billion billion respectively increase borrowings result financing general corporate purposes net cash cash current marketable securities net debt billion compared net cash billion total debt represented total capital shareholders equity total debt total capital shareholders equity per share end compared yearend decrease summary borrowings found note consolidated financial statements johnson johnson annual report contractual obligations commitments companys contractual obligations primarily leases debt unfunded retirement plans significant obligations satisfy obligations company use cash operations following table summarizes companys contractual obligations aggregate maturities december see notes consolidated financial statements details longterm interest unfunded dollars millions debt obligations debt obligations retirement plans operating leases total total tax matters see note consolidated financial statements dividends company increased dividend nd consecutive year cash dividends paid per share compared dividends per share per share dividends distributed follows first quarter second quarter third quarter fourth quarter total january board directors declared regular quarterly cash dividend per share payable march shareholders record february company expects continue practice paying regular cash dividends information critical accounting policies estimates managements discussion analysis results operations financial condition based companys consolidated financial statements prepared accordance accounting principles generally accepted us gaap preparation financial statements requires management make estimates assumptions affect amounts reported revenues expenses assets liabilities related disclosures actual results may may differ estimates company believes understanding certain key accounting policies estimates essential achieving insight companys operating results financial condition key accounting policies include revenue recognition income taxes legal selfinsurance contingencies valuation longlived assets assumptions used determine amounts recorded pensions employee benefit plans accounting stock based awards revenue recognition company recognizes revenue product sales goods shipped delivered title risk loss pass customer provisions certain rebates sales incentives trade promotions coupons product returns discounts customers accounted reductions sales period related sales recorded product discounts granted based terms arrangements direct indirect market participants well market conditions including prices charged competitors rebates include medicaid rebate provision estimated based contractual terms historical experience patient outcomes trend analysis projected market conditions various markets served company evaluates market conditions products groups products primarily johnson johnson annual report analysis wholesaler thirdparty sellthrough market research data well internally generated information sales returns estimated recorded based historical sales returns information products exhibit unusual sales return patterns due dating competition marketing matters specifically investigated analyzed part accounting sales return accruals sales returns allowances represent reserve products may returned due expiration destruction field specific areas product recall returns reserve based historical return trends product market percent gross sales accordance companys accounting policies company generally issues credit customers returned goods companys sales returns reserves accounted accordance us gaap guidance revenue recognition right return exists sales returns reserves recorded full sales value sales returns consumer pharmaceutical segments almost exclusively resalable sales returns certain franchises medical devices segment typically resalable material company infrequently exchanges products inventory returned products sales returns reserve total company approximately annual net trade sales fiscal reporting years promotional programs product listing allowances cooperative advertising arrangements recorded year incurred continuing promotional programs include coupons volumebased sales incentive programs redemption cost consumer coupons based historical redemption experience product value volumebased incentive programs based estimated sales volumes incentive period recorded products sold company also earns service revenue copromotion certain products years presented service revenues less total revenues included sales customers arrangements evaluated determine appropriate amounts deferred addition company enters collaboration arrangements contain multiple revenue generating activities amounts due collaborative partners arrangements recognized activity performed delivered based relative fair value upfront fees received part arrangements deferred recognized performance period see note consolidated financial statements additional disclosures collaborations reasonably likely changes assumptions used calculate accruals rebates returns promotions anticipated material effect financial statements company currently discloses impact changes assumptions quarterly annual filing material financial statement impact johnson johnson annual report tables show progression accrued rebates returns promotions reserve doubtful accounts reserve cash discounts segment business fiscal years ended december december consumer segment balance balance dollars millions beginning period accruals paymentscredits end period accrued rebates accrued returns accrued promotions subtotal reserve doubtful accounts reserve cash discounts total accrued rebates accrued returns accrued promotions subtotal reserve doubtful accounts reserve cash discounts total includes reserve customer rebates million december million december recorded contra asset pharmaceutical segment balance balance dollars millions beginning period accruals paymentscredits end period accrued rebates accrued returns accrued promotions subtotal reserve doubtful accounts reserve cash discounts total accrued rebates accrued returns accrued promotions subtotal reserve doubtful accounts reserve cash discounts total includes reserve customer rebates million december million december recorded contra asset johnson johnson annual report medical devices segment balance balance dollars millions beginning period accruals paymentscredits end period accrued rebates accrued returns accrued promotions subtotal reserve doubtful accounts reserve cash discounts total accrued rebates accrued returns accrued promotions subtotal reserve doubtful accounts reserve cash discounts total includes reserve customer rebates million december million december recorded contra asset income taxes income taxes recorded based amounts refundable payable current year include results difference us gaap accounting tax reporting recorded deferred tax assets liabilities company estimates deferred tax assets liabilities based enacted tax regulations rates future changes tax laws rates may affect recorded deferred tax assets liabilities company unrecognized tax benefits uncertain tax positions company follows us gaap prescribes recognition threshold measurement attribute financial statement recognition measurement tax position taken expected taken tax return management believes changes estimates would material effect company 's results operations cash flows financial position december december cumulative amounts undistributed international earnings approximately billion billion respectively december december company 's foreign subsidiaries held balances cash cash equivalents amounts billion billion respectively company provided deferred taxes undistributed earnings certain international subsidiaries earnings considered permanently reinvested company intends continue reinvest earnings international operations company decided later date repatriate earnings us company would required provide net tax effects amounts company determine deferred tax liability associated undistributed earnings determination practical see note consolidated financial statements information regarding income taxes legal self insurance contingencies company records accruals various contingencies including legal proceedings product liability claims arise normal course business accruals based managements judgment probability losses applicable actuarially determined estimates company self insurance whollyowned captive insurance company addition accruals self insurance program claims exceed insurance coverage accrued losses probable amounts reasonably estimated additionally company records insurance receivable amounts thirdparty insurers recovery probable appropriate reserves receivables recorded estimated amounts may collected thirdparty insurers company follows provisions us gaap recording litigation related contingencies liability recorded loss probable reasonably estimated best estimate loss within range accrued however estimate range better minimum amount accrued johnson johnson annual report longlived intangible assets company assesses changes economic conditions makes assumptions regarding estimated future cash flows evaluating value companys property plant equipment goodwill intangible assets assumptions estimates may change time may may necessary company record impairment charges employee benefit plans company sponsors various retirement pension plans including defined benefit defined contribution termination indemnity plans cover employees worldwide plans based assumptions discount rate expected return plan assets mortality rates expected salary increases health care cost trend rates see note consolidated financial statements details rates effect rate change health care cost trend would companys results operations stock based compensation company recognizes compensation expense associated issuance equity instruments employees services based type equity instrument fair value estimated date grant using either blackscholes option valuation model combination blackscholes option valuation model monte carlo valuation model expensed financial statements vesting period input assumptions used determining fair value expected life expected volatility riskfree rate dividend yield see note consolidated financial statements additional information new accounting pronouncements refer note consolidated financial statements recently adopted accounting pronouncements recently issued accounting pronouncements yet adopted december economic market factors company aware products used environment decade policymakers consumers businesses expressed concerns rising cost health care response concerns company longstanding policy pricing products responsibly period united states weighted average compound annual growth rate companys net price increases health care products prescription overthecounter drugs hospital professional products us consumer price index cpi company operates certain countries economic conditions continue present significant challenges company continues monitor situations take appropriate actions inflation rates continue effect worldwide economies consequently way companies operate company accounted operations venezuela highly inflationary prior threeyear cumulative inflation rate surpassed face increasing costs company strives maintain profit margins cost reduction programs productivity improvements periodic price increases venezuelan government established process establishing alternative systems offerings various foreign currency exchanges company continued access official government rate bolivares fuertes one us dollar settle imports various products venezuela fourth quarter company primarily utilized official government rate bolivares fuertes one us dollar preparing financial statements second fiscal quarter company applied settle outstanding dividend payable one alternative foreign exchange rates result company applied alternative exchange rate translate certain transactions appropriate december companys venezuelan subsidiaries represented less company 's consolidated assets liabilities revenues profits therefore effect change exchange rate expected material adverse effect company 's fullyear results company exposed fluctuations currency exchange rates change value us dollar compared foreign currencies company sales income expense would increased decreased translation foreign sales approximately million income million company faces various worldwide health care changes may continue result pricing pressures include health care cost containment government legislation relating sales promotions reimbursement health care products changes behavior spending patterns purchasers health care products services including delaying medical procedures rationing prescription medications reducing frequency physician visits foregoing health care insurance coverage result current global economic downturn may continue impact companys businesses company also operates environment increasingly hostile intellectual property rights firms filed abbreviated new drug applications biosimilar biological product applications fda otherwise challenged coverage andor validity company 's patents seeking market generic biosimilar forms many companys key pharmaceutical products prior expiration applicable patents covering products event company successful defending patent claims challenged resulting lawsuits generic biosimilar versions products issue introduced market resulting potential substantial market share revenue losses products may result noncash impairment charge associated intangible asset information see johnson johnson annual report discussion remicade related cases litigation filers abbreviated new drug applications note consolidated financial statements legal proceedings johnson johnson certain subsidiaries involved various lawsuits claims regarding product liability intellectual property commercial matters governmental investigations legal proceedings arise time time ordinary course business company records accruals contingencies probable liability incurred amount loss reasonably estimated company accrued certain litigation matters continues monitor related legal issue adjust accruals new information developments accordance accounting standards codification asc litigation regulatory matters currently disclosed loss probable reasonably possible company unable determine estimate possible loss range loss beyond amounts already accrued matters affected various factors including whether damages sought proceedings unsubstantiated indeterminate scientific legal discovery commenced complete proceedings early stages matters present legal uncertainties significant facts dispute numerous parties involved company 's opinion based examination matters experience date discussions counsel ultimate outcome legal proceedings net liabilities accrued company 's balance sheet expected material adverse effect company 's financial position however resolution reporting period one matters either alone aggregate may material adverse effect company 's results operations cash flows period see note consolidated financial statements information regarding legal proceedings common stock market prices companys common stock listed new york stock exchange symbol jnj february record holders common stock company composite market price ranges johnson johnson common stock high low high low first quarter second quarter third quarter fourth quarter yearend close johnson johnson annual report cautionary factors may affect future results annual report contains forwardlooking statements forwardlooking statements relate strictly historical current facts anticipate results based managements plans subject uncertainty forwardlooking statements may identified use words plans expects anticipates estimates words similar meaning conjunction among things discussions future operations financial performance companys strategy growth product development regulatory approval market position expenditures forwardlooking statements based current expectations future events company guarantee forwardlooking statement accurate although company believes reasonable expectations assumptions investors realize underlying assumptions prove inaccurate known unknown risks uncertainties materialize actual results could vary materially companys expectations projections investors therefore cautioned place undue reliance forwardlooking statements company undertake update forwardlooking statements result new information future events developments risks uncertainties include limited economic factors interest rate currency exchange rate fluctuations competition including technological advances new products patents attained competitors challenges inherent new product development including obtaining regulatory approvals challenges patents impact patent expirations uncertainty commercial success new existing products significant adverse litigation government action including related product liability claims impact business combinations divestitures significant changes customer relationships changes behavior spending patterns financial distress purchasers health care products services changes laws regulations global health care reforms trends toward health care cost containment increased scrutiny health care industry government agencies financial instability international economies sovereign risk manufacturing difficulties delays complex global supply chains increasing regulatory requirements product efficacy safety concerns resulting product recalls regulatory action disruptions due natural disasters potential failure meet obligations compliance agreements government bodies discussion factors could cause actual results differ materially expectations found annual report fiscal year ended december including exhibit company notes factors permitted private securities litigation reform act johnson johnson annual report johnson johnson subsidiaries consolidated balance sheets december december dollars millions except share per share amounts note assets current assets cash cash equivalents notes marketable securities notes accounts receivable trade less allowances doubtful accounts inventories notes deferred taxes income note prepaid expenses receivables total current assets property plant equipment net notes intangible assets net notes goodwill notes deferred taxes income note assets total assets liabilities shareholders equity current liabilities loans notes payable note accounts payable accrued liabilities accrued rebates returns promotions accrued compensation employee related obligations accrued taxes income total current liabilities longterm debt note deferred taxes income note employee related obligations notes liabilities total liabilities shareholders equity preferred stock without par value authorized unissued shares common stock par value per share note authorized shares issued shares accumulated comprehensive income note retained earnings less common stock held treasury cost note shares shares total shareholders equity total liabilities shareholders equity see notes consolidated financial statements johnson johnson annual report johnson johnson subsidiaries consolidated statements earnings dollars shares millions except per share amounts note sales customers cost products sold gross profit selling marketing administrative expenses research development expense inprocess research development interest income interest expense net portion capitalized note income expense net earnings provision taxes income provision taxes income note net earnings add net loss attributable noncontrolling interest net earnings attributable johnson johnson net earnings per share attributable johnson johnson notes basic diluted cash dividends per share average shares outstanding notes basic diluted see notes consolidated financial statements johnson johnson annual report johnson johnson subsidiaries consolidated statements comprehensive income dollars millions note net earnings comprehensive income loss net tax foreign currency translation securities unrealized holding gain loss arising period reclassifications earnings net change employee benefit plans prior service cost amortization period prior service credit cost current year gain amortization period gain loss current year effect exchange rates net change derivatives hedges unrealized gain loss arising period reclassifications earnings net change comprehensive income loss comprehensive income comprehensive loss attributable noncontrolling interest net tax comprehensive income attributable johnson johnson tax effects comprehensive income fiscal years ended respectively securities million million million employee benefit plans million million million derivatives hedges million million million see notes consolidated financial statements johnson johnson annual report johnson johnson subsidiaries consolidated statements equity dollars millions note accumulated treasury retained comprehensive common stock stock total earnings income issued amount amount balance january net earnings attributable johnson johnson cash dividends paid employee compensation stock option plans issuance common stock associated acquisition synthes inc repurchase common stock comprehensive income loss net tax balance december net earnings attributable johnson johnson cash dividends paid employee compensation stock option plans repurchase common stock comprehensive income loss net tax balance december net earnings attributable johnson johnson cash dividends paid employee compensation stock option plans repurchase common stock comprehensive income loss net tax balance december includes repurchase common stock associated acquisition synthes inc see notes consolidated financial statements johnson johnson annual report johnson johnson subsidiaries consolidated statements cash flows dollars millions note cash flows operating activities net earnings adjustments reconcile net earnings cash flows operating activities depreciation amortization property intangibles stock based compensation noncontrolling interest venezuela adjustments asset writedowns net gain sale assetsbusinesses net gain equity investment transactions deferred tax provision accounts receivable allowances changes assets liabilities net effects acquisitions divestitures increase accounts receivable increase inventories increase accounts payable accrued liabilities decreaseincrease current noncurrent assets decreaseincrease current noncurrent liabilities net cash flows operating activities cash flows investing activities additions property plant equipment proceeds disposal assetsbusinesses net acquisitions net cash acquired note purchases investments sales investments primarily intangibles net cash used investing activities cash flows financing activities dividends shareholders repurchase common stock proceeds shortterm debt retirement shortterm debt proceeds longterm debt retirement longterm debt proceeds exercise stock optionsexcess tax benefits net cash used financing activities effect exchange rate changes cash cash equivalents decreaseincrease cash cash equivalents cash cash equivalents beginning year note cash cash equivalents end year note supplemental cash flow data cash paid year interest interest net amount capitalized income taxes johnson johnson annual report supplemental schedule noncash investing financing activities issuance common stock associated acquisition synthes inc treasury stock issued employee compensation stock option plans net cash proceeds conversion debt acquisitions fair value assets acquired fair value liabilities assumed noncontrolling interests net fair value acquisitions less issuance common stock associated acquisition synthes inc net cash paid acquisitions see notes consolidated financial statements johnson johnson annual report notes consolidated financial statements summary significant accounting policies principles consolidation consolidated financial statements include accounts johnson johnson subsidiaries company intercompany accounts transactions eliminated description company business segments company approximately employees worldwide engaged research development manufacture sale broad range products health care field company conducts business virtually countries world primary focus products related human health wellbeing company organized three business segments consumer pharmaceutical medical devices previously referred medical devices diagnostics consumer segment includes broad range products used baby care oral care skin care overthecounter pharmaceutical womens health wound care markets products marketed general public sold retail outlets distributors throughout world pharmaceutical segment focused five therapeutic areas including immunology infectious diseases neuroscience oncology cardiovascular metabolic diseases products segment distributed directly retailers wholesalers hospitals health care professionals prescription use medical devices segment includes broad range products used orthopaedic surgical care specialty surgery cardiovascular care diagnostics diabetes care vision care markets distributed wholesalers hospitals retailers used principally professional fields physicians nurses hospitals clinics new accounting pronouncements recently adopted accounting pronouncements fiscal first quarter company adopted financial accounting standards board fasb guidance clarifying release accumulated foreign currency translation comprehensive income oci current year net earnings amendment requires parent company ceases controlling interest subsidiary business within foreign entity parent release accumulated foreign currency translation oci update became effective annual periods interim reporting periods beginning december adoption standard material impact company 's results operations cash flows financial position fiscal first quarter company adopted fasb guidance presentation unrecognized tax benefits various qualifying tax credits exist amendment requires unrecognized tax benefits presented consolidated balance sheet reduction deferred tax assets created net operating losses tax credits prior periods occur taxing jurisdiction extent unrecognized tax benefit exceeds credits shall presented liability update became effective annual periods interim reporting periods beginning december adoption standard material impact presentation company 's financial position fiscal second quarter fasb issued amended guidance use presentation discontinued operations entitys financial statements new guidance restricts presentation discontinued operations business circumstances disposal business operations represents strategic shift major effect entitys operations financial results examples strategic shift could include limited disposal major geographic segments major line business major business component entity new guidance also expands required disclosures entities assets held sale meet new definition discontinued operations amendment includes early adoption provisions allowing company implement update immediately first quarter company elected adopt standard first quarter balances updated disclosures required amended guidance included note notes consolidated financial statements fiscal second quarter fasb issuedaccounting standards update accounting sharebased payments terms award provide performance target could achieved requisite service period standard clarifies current accounting guidance entities issue sharebased payment awards require specific performance target achieved employees become eligible vest awards may occur subsequent required service period current accounting guidance explicitly address account types awards new standard provides explicit guidance clarifies types performance targets treated performance conditions accounting sharebased awards performance conditions already specified current johnson johnson annual report accounting guidance update required adopted public companies annual periods interim reporting periods beginning december early adoption standard permitted company elected adopt standardfor second quarter adoption standard material impact company 's results operations cash flows financial position recently issued accounting standards adopted december fiscal second quarter fasb issued accounting standards update revenue contracts customers standard replaces substantially current revenue recognition accounting guidance update required adopted public companies annual periods interim reporting periods beginning december early adoption standard permitted company currently assessing impact future adoption standard financial statements fiscal second quarter fasb issued amended guidance accounting standards update development stage entities elimination certain financial reporting requirements including amendment variable interest entity guidance topic consolidation change current guidance require company determine consolidate one entities based change consolidation analysis update consolidation analysis become effective annual periods interim reporting periods beginning december adoption standard expected material impact presentation company 's results operations cash flows financial position fiscal third quarter fasb issued accounting standards update disclosure uncertainties entitys ability continue going concern standard requires management evaluate annual interim reporting period whether conditions events considered aggregate raise substantial doubt entitys ability continue going concern within one year date financial statements issued available issued substantial doubt raised additional disclosures around managements plan alleviate doubts required update become effective annual periods interim reporting periods beginning december standard expected impact current disclosures financial statements cash equivalents company classifies highly liquid investments stated maturities three months less date purchase cash equivalents highly liquid investments stated maturities greater three months date purchase current marketable securities company policy making investments commercial institutions least equivalent credit rating company invests cash primarily reverse repurchase agreements rras government securities obligations corporate debt securities money market funds rras collateralized deposits form government securities obligations amount less value company record asset liability company permitted sell repledge associated collateral company policy collateral least equivalent credit rating company utilizes third party custodian manage exchange funds ensure collateral received maintained value rras daily basis rras stated maturities greater three months date purchase classified marketable securities investments shortterm marketable securities carried cost approximates fair value investments classified availableforsale carried estimated fair value unrealized gains losses recorded component accumulated comprehensive income longterm debt securities company ability intent hold maturity carried amortized cost management determines appropriate classification investment debt equity securities time purchase reevaluates determination balance sheet date company periodically reviews investments equity securities impairment adjusts investments fair value decline market value deemed temporary losses securities considered temporary loss recognized earnings property plant equipment depreciation property plant equipment stated cost company utilizes straightline method depreciation estimated useful lives assets johnson johnson annual report building building equipment years land leasehold improvements years machinery equipment years company capitalizes certain computer software development costs included machinery equipment incurred connection developing obtaining computer software internal use capitalized software costs amortized estimated useful lives software generally range years company reviews longlived assets assess recoverability using undiscounted cash flows certain events changes operating economic conditions occur impairment assessment may performed recoverability carrying value assets asset determined impaired loss measured based difference assets fair value carrying value quoted market prices available company estimate fair value using discounted value estimated future cash flows revenue recognition company recognizes revenue product sales goods shipped delivered title risk loss pass customer provisions certain rebates sales incentives trade promotions coupons product returns discounts customers accounted reductions sales period related sales recorded product discounts granted based terms arrangements direct indirect market participants well market conditions including prices charged competitors rebates include medicaid estimated based contractual terms historical experience patient outcomes trend analysis projected market conditions various markets served company evaluates market conditions products groups products primarily analysis wholesaler thirdparty sellthrough market research data well internally generated information sales returns generally estimated recorded based historical sales returns information products exhibit unusual sales return patterns due dating competition marketing matters specifically investigated analyzed part accounting sales returns accruals sales returns allowances represent reserve products may returned due expiration destruction field specific areas product recall returns reserve based historical return trends product market percent gross sales accordance companys accounting policies company generally issues credit customers returned goods companys sales returns reserves accounted accordance us gaap guidance revenue recognition right return exists sales returns reserves recorded full sales value sales returns consumer pharmaceutical segments almost exclusively resalable sales returns certain franchises medical devices segment typically resalable material company infrequently exchanges products inventory returned products sales returns reserve total company approximately annual sales customers fiscal reporting years promotional programs product listing allowances cooperative advertising arrangements recorded year incurred continuing promotional programs include coupons volumebased sales incentive programs redemption cost consumer coupons based historical redemption experience product value volumebased incentive programs based estimated sales volumes incentive period recorded products sold company also earns service revenue copromotion certain products includes sales customers arrangements evaluated determine appropriate amounts deferred shipping handling shipping handling costs incurred million million million respectively included selling marketing administrative expense amount revenue received shipping handling less sales customers periods presented inventories inventories stated lower cost market determined firstin firstout method intangible assets goodwill authoritative literature us gaap requires goodwill intangible assets indefinite lives assessed annually impairment company completed annual impairment test fiscal fourth quarter future impairment tests performed annually fiscal fourth quarter sooner warranted purchased inprocess research development accounted indefinite lived intangible asset underlying project completed point intangible asset accounted definite lived intangible asset abandoned point intangible asset written partially impaired intangible assets finite useful lives continue amortized useful lives reviewed impairment warranted economic conditions see note details intangible assets goodwill johnson johnson annual report financial instruments required us gaap derivative instruments recorded balance sheet fair value fair value exit price would received sell asset paid transfer liability fair value marketbased measurement determined using assumptions market participants would use pricing asset liability authoritative literature establishes threelevel hierarchy prioritize inputs used measuring fair value level highest priority level lowest changes fair value derivatives recorded period current earnings comprehensive income depending whether derivative designated part hedge transaction type hedge transaction company documents relationships hedged items derivatives overall risk management strategy includes reasons undertaking hedge transactions entering derivatives objectives strategy minimize foreign currency exposures impact companys financial performance protect companys cash flow adverse movements foreign exchange rates ensure appropriateness financial instruments manage enterprise risk associated financial institutions see note additional information financial instruments product liability accruals product liability claims recorded undiscounted basis probable liability incurred amount liability reasonably estimated based existing information accruals adjusted periodically additional information becomes available company accrues estimate legal defense costs needed defend matter referred defense costs connection product liability litigation certain matters indemnity amount also recorded referred product liability accrual result cost availability factors effective november company ceased purchasing thirdparty product liability insurance company self insurance whollyowned captive insurance company addition accruals self insurance program claims exceed insurance coverage accrued losses probable amounts reasonably estimated based availability prior coverage receivables insurance recoveries related product liability claims recorded undiscounted basis probable recovery realized appropriate reserves receivables recorded estimated amounts may collected thirdparty insurers concentration credit risk global concentration credit risk respect trade accounts receivables continues limited due large number customers globally adherence internal credit policies credit limits economic challenges italy spain greece portugal southern european region impacted certain payment patterns historically longer experienced us international markets total net trade accounts receivable balance southern european region approximately billion december approximately billion december approximately billion december approximately billion december southern european region net trade accounts receivable balance related company 's consumer vision care diabetes care businesses well certain pharmaceutical medical devices customers line historical collection patterns remaining balance net trade accounts receivable southern european region negatively impacted timing payments certain government owned supported health care customers well certain distributors pharmaceutical medical devices local affiliates total net trade accounts receivable balance customers approximately billion december billion december company continues receive payments customers cases late payment premiums customers payment expected periods time longer one year revenue trade receivables discounted estimated period time collection allowances doubtful accounts increased customers immaterial date company continue work closely customers payment plans monitor economic situation take appropriate actions necessary research development research development expenses expensed incurred upfront milestone payments made third parties connection research development collaborations expensed incurred point regulatory approval payments made third parties subsequent regulatory approval capitalized amortized remaining useful life related product amounts capitalized payments included intangibles net accumulated amortization company enters collaborative arrangements typically pharmaceutical biotechnology companies develop commercialize drug candidates intellectual property arrangements typically involve two parties active participants collaboration exposed significant risks rewards dependent commercial success activities collaborations usually involve various activities one parties including johnson johnson annual report research development marketing selling distribution often collaborations require upfront milestone royalty profit share payments contingent upon occurrence certain future events linked success asset development amounts due collaborative partners related development activities generally reflected reduction research development expense performance contract development services central companys operations general income statement presentation collaborations follows naturetype collaboration statement earnings presentation thirdparty sale product sales customers royaltiesmilestones paid collaborative partner postregulatory cost products sold approval royalties received collaborative partner income expense net upfront payments milestones paid collaborative partner research development expense preregulatory approval research development payments collaborative partner research development expense research development payments received collaborative partner reduction research development expense milestones capitalized intangible assets amortized cost goods sold useful life years presented individual project represented greater total annual consolidated research development expense advertising costs associated advertising expensed year incurred included selling marketing administrative expenses advertising expenses worldwide comprised television radio print media internet advertising billion billion billion respectively income taxes income taxes recorded based amounts refundable payable current year include results difference us gaap accounting tax reporting recorded deferred tax assets liabilities company estimates deferred tax assets liabilities based enacted tax regulations rates future changes tax laws rates may affect recorded deferred tax assets liabilities future company unrecognized tax benefits uncertain tax positions company follows us gaap prescribes recognition threshold measurement attribute financial statement recognition measurement tax position taken expected taken tax return management believes changes estimates would material effect company 's results operations cash flows financial position december december cumulative amounts undistributed international earnings approximately billion billion respectively december december company 's foreign subsidiaries held balances cash cash equivalents amounts billion billion respectively company provided deferred taxes undistributed earnings certain international subsidiaries earnings considered permanently reinvested company intends continue reinvest earnings international operations company decided later date repatriate earnings us company would required provide net tax effects amounts company determine deferred tax liability associated undistributed earnings determination practical see note consolidated financial statements information regarding income taxes net earnings per share basic earnings per share computed dividing net earnings available common shareholders weighted average number common shares outstanding period diluted earnings per share reflects potential dilution could occur securities exercised converted common stock using treasury stock method use estimates preparation consolidated financial statements conformity accounting principles generally accepted us requires management make estimates assumptions affect amounts reported estimates used accounting sales discounts rebates allowances incentives product liabilities income taxes depreciation amortization employee benefits contingencies intangible asset liability valuations actual results may may differ estimates johnson johnson annual report company follows provisions us gaap recording litigation related contingencies liability recorded loss probable reasonably estimated best estimate loss within range accrued however estimate range better minimum amount accrued annual closing date company follows concept fiscal year ends sunday nearest end month december normally fiscal year consists weeks every five six years fiscal year consists weeks case case reclassification certain prior period amounts reclassified conform current year presentation cash cash equivalents current marketable securities end cash cash equivalents current marketable securities comprised dollars millions cash government securities obligations reverse repurchase agreements corporate debt securities money market funds time deposits total cash cash equivalents current marketable securities estimated fair value approximated cost december december december current marketable securities consisted million million government securities obligations corporate debt securities respectively reverse repurchase agreements december current marketable securities consisted million million million government securities obligations reverse repurchase agreements corporate debt securities respectively fair value government securities obligations corporate debt securities estimated using quoted broker prices significant observable inputs company invests excess cash deposits major banks throughout world highquality money market instruments company policy making investments commercial institutions least equivalent credit rating inventories end inventories comprised dollars millions raw materials supplies goods process finished goods total inventories property plant equipment end property plant equipment cost accumulated depreciation johnson johnson annual report dollars millions land land improvements buildings building equipment machinery equipment construction progress total property plant equipment gross less accumulated depreciation total property plant equipment net company capitalizes interest expense part cost construction facilities equipment interest expense capitalized million million million respectively depreciation expense including amortization capitalized interest billion billion billion respectively upon retirement disposal property plant equipment costs related amounts accumulated depreciation amortization eliminated asset accumulated depreciation accounts respectively difference net asset value proceeds recorded earnings intangible assets goodwill end gross net amounts intangible assets dollars millions intangible assets definite lives patents trademarks gross less accumulated amortization patents trademarks net customer relationships intangibles gross less accumulated amortization customer relationships intangibles net intangible assets indefinite lives trademarks purchased inprocess research development total intangible assets indefinite lives total intangible assets net goodwill december december allocated segment business follows dollars millions consumer pharmaceutical med devices total goodwill december goodwill related acquisitions goodwill related divestitures currency translationother goodwill december goodwill related acquisitions goodwill related divestitures currency translationother goodwill december weighted average amortization periods patents trademarks customer relationships intangible assets years years respectively amortization expense amortizable assets included cost products sold million million million tax fiscal years ended december december johnson johnson annual report december respectively estimated amortization expense five succeeding years approximates million tax per year see note consolidated financial statements additional details related acquisitions divestitures fair value measurements company uses forward foreign exchange contracts manage exposure variability cash flows primarily related foreign exchange rate changes future intercompany product thirdparty purchases materials denominated foreign currency company uses cross currency interest rate swaps manage currency risk primarily related borrowings types derivatives designated cash flow hedges additionally company uses interest rate swaps instrument manage interest rate risk related fixed rate borrowings derivatives treated fair value hedges company may use forward foreign exchange contracts designated net investment hedges additionally company uses forward foreign exchange contracts offset exposure certain foreign currency assets liabilities forward foreign exchange contracts designated hedges therefore changes fair values derivatives recognized earnings thereby offsetting current earnings effect related foreign currency assets liabilities company enter derivative financial instruments trading speculative purposes contain credit risk related contingent features requirements post collateral ongoing basis company monitors counterparty credit ratings company considers credit nonperformance risk low company enters agreements commercial institutions least equivalent credit rating december company notional amounts outstanding forward foreign exchange contracts cross currency interest rate swaps interest rate swaps billion billion billion respectively derivative instruments recorded balance sheet fair value changes fair value derivatives recorded period current earnings comprehensive income depending whether derivative designated part hedge transaction type hedge transaction designation cash flow hedge made entrance date derivative contract inception derivatives expected highly effective changes fair value derivative designated cash flow hedge highly effective recorded accumulated comprehensive income underlying transaction affects earnings reclassified earnings account hedged transaction gains losses associated interest rate swaps recorded interest expense period occur gains losses net investment hedges accounted currency translation account insignificant ongoing basis company assesses whether derivative continues highly effective offsetting changes hedged items derivative longer expected highly effective hedge accounting discontinued hedge ineffectiveness included current period earnings income expense net forward foreign exchange contracts cross currency interest rate swaps interest rate swaps designated fair value hedges hedge ineffectiveness included current period earnings within interest expense current reporting period hedge ineffectiveness associated interest rate swaps material december balance deferred net gains derivatives included accumulated comprehensive income million aftertax additional information see consolidated statements comprehensive income note company expects substantially amounts related forward foreign exchange contracts reclassified earnings next months result transactions expected occur period maximum length time company hedging transaction exposure months excluding interest rate contracts amount ultimately realized earnings may differ foreign exchange rates change realized gains losses ultimately determined actual exchange rates maturity derivative following table summary activity related derivatives designated cash flow hedges fiscal years ended december december johnson johnson annual report gainloss reclassified gainloss recognized accumulated accumulated oci gainloss recognized dollars millions oci income incomeexpense cash flow hedges income statement caption sales customers cost products sold research development expense interest incomeinterest expense net income expense net total amounts shown table net tax effective portion ineffective portion forward foreign exchange contracts cross currency interest rate swaps fiscal years ended december december gain million gain million respectively recognized income expense net relating forward foreign exchange contracts designated hedging instruments fair value exit price would received sell asset paid transfer liability fair value marketbased measurement determined using assumptions market participants would use pricing asset liability authoritative literature establishes threelevel hierarchy prioritize inputs used measuring fair value levels within hierarchy described level highest priority level lowest fair value derivative financial instrument ie forward foreign exchange contracts interest rate contracts aggregation currency future cash flows discounted present value prevailing market interest rates subsequently converted us dollar current spot foreign exchange rate company believe fair values derivative instruments materially differ amounts could realized upon settlement maturity changes fair value material effect companys results operations cash flows financial position company also holds equity investments classified level traded active exchange market company significant financial assets liabilities would require revised valuations standard recognized fair value following three levels inputs used measure fair value level quoted prices active markets identical assets liabilities level significant observable inputs level significant unobservable inputs companys significant financial assets liabilities measured fair value december december follows johnson johnson annual report dollars millions level level level total total derivatives designated hedging instruments assets forward foreign exchange contracts interest rate contracts total liabilities forward foreign exchange contracts interest rate contracts total derivatives designated hedging instruments assets forward foreign exchange contracts liabilities forward foreign exchange contracts investments assets liabilities classified level exception investments million classified level includes million million noncurrent assets fiscal years ending december december respectively includes million million noncurrent liabilities fiscal years ending december december respectively includes cross currency interest rate swaps interest rate swaps classified noncurrent assets see notes financial assets liabilities held carrying amount consolidated balance sheet johnson johnson annual report borrowings components longterm debt follows dollars millions effective rate effective rate month libor frn due notes due notes due month libor frn due notes due debentures due notes due debentures due notes due notes due b euro b euro notes due zero coupon convertible subordinated debentures due debentures due notes due notes due debentures due notes due notes due mm gbp mm gbp notes due debentures due notes due notes due debentures due debentures due notes due notes due subtotal less current portion total longterm debt weighted average effective rate translation rate december translation rate december excess fair value carrying value debt billion billion includes reopening issues fair value noncurrent debt estimated using market prices corroborated quoted broker prices significant observable inputs company access substantial sources funds numerous banks worldwide september company secured new day credit facility total credit available company approximates billion expires september interest charged borrowings credit line agreements based either bids provided johnson johnson annual report banks prime rate london interbank offered rates libor plus applicable margins commitment fees agreements material throughout company continued access liquidity commercial paper market shortterm borrowings current portion longterm debt amounted approximately billion end billion borrowed commercial paper program remainder principally represents local borrowing international subsidiaries company shelf registration us securities exchange commission enables company issue debt securities warrants purchase debt securities timely basis company issued bonds november total billion general corporate purposes included reopening bonds issues december aggregate maturities longterm obligations commencing dollars millions income taxes provision taxes income consists dollars millions currently payable us taxes international taxes total currently payable deferred us taxes international taxes total deferred provision taxes income comparison income tax expense us statutory rate companys effective tax rate follows dollars millions us international earnings taxes income tax rates us statutory rate international operations excluding ireland ireland puerto rico operations research orphan drug tax credits us state local us manufacturing deduction us tax international income us tax benefit assetbusiness disposals effective tax rate johnson johnson annual report increase effective tax rate compared attributable following divestiture orthoclinical diagnostics business approximate effective tax rate litigation accruals low tax rates mix earnings higher tax jurisdictions primarily us accrual additional year branded prescription drug fee tax deductible additional us tax expense related planned increase dividends current year foreign earnings compared prior year increases effective tax rate partially offset tax benefit billion associated conor medsystems divestiture effective tax rate reduced tax benefit associated writeoff assets tax purposes associated scios inc inclusion benefit research development tax credit controlled foreign corporation lookthrough provisions provisions enacted law january retroactive january effective tax rate also reduced company adjusted unrecognized tax benefits result federal appeals courts decision omj pharmaceuticals incs litigation regarding credits former section internal revenue code see note consolidated financial statements additional information ii settlement substantially issues related companys us internal revenue service audit tax years impact settlement reflected us tax international income line items within reconciliation items noted reflect key drivers rate reconciliation company subsidiaries operating puerto rico various tax incentives temporary differences carryforwards follows deferred tax deferred tax dollars millions asset liability asset liability employee related obligations stock based compensation depreciation nondeductible intangibles international rd capitalized tax reserves liabilities income reported tax purposes net operating loss carryforward international miscellaneous international miscellaneous us total deferred income taxes million net valuation allowance related belgium million million net valuation allowance related belgium million difference net deferred tax income per balance sheet net deferred tax included taxes income balance sheet company whollyowned international subsidiaries cumulative net losses company believes likely subsidiaries realize future taxable income sufficient utilize deferred tax assets following table summarizes activity related unrecognized tax benefits dollars millions beginning year increases related current year tax positions increases related prior period tax positions decreases related prior period tax positions settlements lapse statute limitations end year unrecognized tax benefits billion december recognized would affect companys annual effective tax rate company conducts business files tax returns numerous countries currently tax audits johnson johnson annual report progress number tax authorities irs completed audit tax years however limited number issues remaining open prior tax years going back major jurisdictions company conducts business years remain open generally back year company believes possible audits may completed tax authorities jurisdictions next twelve months however company able provide reasonably reliable estimate timing future tax payments relating uncertain tax positions company classifies liabilities unrecognized tax benefits related interest penalties longterm liabilities interest expense penalties related unrecognized tax benefits classified income tax expense company recognized tax interest expense million million million respectively total amount accrued interest million million respectively employee related obligations end employee related obligations recorded consolidated balance sheets dollars millions pension benefits postretirement benefits postemployment benefits deferred compensation total employee obligations less current benefits payable employee related obligations noncurrent prepaid employee related obligations million million respectively included assets consolidated balance sheets pensions benefit plans company sponsors various retirement pension plans including defined benefit defined contribution termination indemnity plans cover employees worldwide company also provides postretirement benefits primarily health care eligible us retired employees dependents many international employees covered governmentsponsored programs cost company significant retirement plan benefits employees hired january primarily based employees compensation last three five years retirement number years service company announced us defined benefit plan amended adopt new benefit formula effective employees hired january benefits calculated using new formula based employee compensation total years service international subsidiaries plans funds deposited trustees annuities purchased group contracts reserves provided company fund retiree health care benefits advance right modify plans future company uses date consolidated financial statements december december respectively measurement date us international retirement benefit plans net periodic benefit costs companys defined benefit retirement plans benefit plans include following components retirement plans benefit plans dollars millions service cost interest cost expected return plan assets amortization prior service cost credit amortization net transition obligation recognized actuarial losses curtailments settlements net periodic benefit cost johnson johnson annual report amounts expected recognized net periodic benefit cost coming year companys defined benefit retirement plans postretirement plans dollars millions amortization net transition obligation amortization net actuarial losses amortization prior service credit unrecognized gains losses us pension plans amortized average remaining future service plan plans active employees amortized average life expectancy amortization gains losses us benefit plans determined using corridor greater market value assets projected benefit obligation total unamortized gains losses excess corridor amortized average remaining future service prior service costsbenefits us pension plans amortized remaining future service plan participants time plan amendment prior service costbenefit us benefit plans amortized average remaining service full eligibility age plan participants time plan amendment weightedaverage assumptions following table represent rates used develop actuarial present value projected benefit obligation year listed also net periodic benefit cost following year retirement plans benefit plans worldwide benefit plans discount rate expected longterm rate return plan assets rate increase compensation levels companys discount rates determined considering current yield curves representing high quality longterm fixed income instruments resulting discount rates consistent duration plan liabilities expected rates return plan asset assumptions represent company 's assessment longterm returns diversified investment portfolios globally assessment determined using projections external financial sources longterm historical averages actual returns asset class various asset class allocations market measurement us retirement benefit obligations mortality assumption updated newly established mortality table resulting increase projected benefit obligation following table displays assumed health care cost trend rates individuals health care plans health care cost trend rate assumed next year rate cost trend rate assumed decline ultimate trend year rate reaches ultimate trend rate onepercentagepoint change assumed health care cost trend rates would following effect onepercentage onepercentage dollars millions point increase point decrease health care plans total interest service cost postretirement benefit obligation johnson johnson annual report following table sets forth information related benefit obligation fair value plan assets yearend companys defined benefit retirement plans postretirement plans retirement plans benefit plans dollars millions change benefit obligation projected benefit obligation beginning year service cost interest cost plan participant contributions amendments actuarial gains losses divestitures acquisitions curtailments settlements restructuring benefits paid plan effect exchange rates projected benefit obligation end year change plan assets plan assets fair value beginning year actual return plan assets company contributions plan participant contributions settlements divestitures acquisitions benefits paid plan assets effect exchange rates plan assets fair value end year funded status end year amounts recognized companys balance sheet consist following noncurrent assets current liabilities noncurrent liabilities total recognized consolidated balance sheet end year amounts recognized accumulated comprehensive income consist following net actuarial loss prior service cost credit unrecognized net transition obligation total tax effects accumulated benefit obligations end year johnson johnson annual report retirement plans benefit plans dollars millions changes plan assets benefit obligations recognized comprehensive income net periodic benefit cost net actuarial gain loss amortization net actuarial loss prior service cost credit amortization prior service cost credit effect exchange rates total recognized comprehensive income tax total recognized net periodic benefit cost comprehensive income company plans continue fund us qualified plans comply pension protection act international plans funded accordance local regulations additional discretionary contributions made deemed appropriate meet longterm obligations plans certain plans funding common practice funding provides economic benefit consequently company several pension plans funded company contributed million million us international pension plans respectively following table displays funded status company 's us qualified nonqualified pension plans international funded unfunded pension plans december december respectively us plans international plans qualified plans nonqualified plans funded plans unfunded plans dollars millions plan assets projected benefit obligation accumulated benefit obligation funded status projected benefit obligation accumulated benefit obligation plans accumulated benefit obligations excess plan assets accumulated benefit obligation projected benefit obligation plan assets billion billion billion respectively end billion billion billion respectively end following table displays projected future benefit payments companys retirement benefit plans dollars millions projected future benefit payments retirement plans benefit plans following table displays projected future minimum contributions unfunded retirement plans amounts include discretionary contributions company may elect make future dollars millions projected future contributions johnson johnson annual report pension plan overseen local committee board responsible overall administration investment pension plans determining investment policies strategies goals committee board considers factors including local pension rules regulations local tax regulations availability investment vehicles separate accounts commingled accounts insurance funds etc funded status plans ratio actives retirees duration liabilities relevant factors including diversification liquidity local markets liquidity base currency majority companys pension funds open new entrants expected ongoing plans permitted investments primarily liquid andor listed little reliance illiquid nontraditional investments hedge funds companys retirement plan asset allocation end target allocations follows percent target plan assets allocation worldwide retirement plans equity securities debt securities total plan assets determination fair value plan assets plan established welldocumented process determining fair values fair value based upon quoted market prices available listed prices quotes available fair value based upon models primarily use inputs marketbased independently sourced market parameters including yield curves interest rates volatilities equity debt prices foreign exchange rates credit curves plan believes valuation methods appropriate consistent market participants use different methodologies assumptions determine fair value certain financial instruments could result different estimate fair value reporting date valuation hierarchy authoritative literature establishes threelevel hierarchy prioritize inputs used measuring fair value levels within hierarchy described table level highest priority level lowest financial instruments categorization within valuation hierarchy based upon lowest level input significant fair value measurement following description valuation methodologies used investments measured fair value shortterm investments cash quoted shortterm instruments valued closing price amount held deposit custodian bank investments investment vehicles valued using net asset value nav provided administrator fund nav based value underlying assets owned fund minus liabilities divided number shares outstanding nav quoted price market active classified level government agency securities limited number investments valued closing price reported major market individual securities traded quoted prices available active market investments classified within level valuation hierarchy quoted market prices available specific security fair values estimated using pricing models quoted prices securities similar characteristics discounted cash flows quoted market prices security available active market classified level debt instruments limited number investments valued closing price reported major market individual securities traded quoted prices available active market investments classified level quoted market prices available specific security fair values estimated using pricing models quoted prices securities similar characteristics discounted cash flows classified level level debt instruments priced based unobservable inputs equity securities common stocks valued closing price reported major market individual securities traded substantially common stock classified within level valuation hierarchy commingled funds investment vehicles valued using nav provided fund administrator nav based value underlying assets owned fund minus liabilities divided number shares outstanding assets level category quoted market price market active johnson johnson annual report insurance contracts instruments issued insurance companies fair value based negotiated value underlying investments held separate account portfolios well considering credit worthiness issuer underlying investments government assetbacked fixed income securities general insurance contracts classified level quoted prices observable inputs pricing assets assets represented primarily limited partnerships real estate investments well commercial loans commercial mortgages classified corporate debt assets exchange listed actively traded classified level inactively traded assets classified level limited partnerships represent investments private equity similar funds valued general partners certain limited partnerships well assets valued using unobservable inputs classified level following table sets forth retirement plans ' investments measured fair value december december quoted prices significant active significant markets observable unobservable identical assets inputs inputs level level level total assets dollars millions shortterm investment funds government agency securities debt instruments equity securities commingled funds insurance contracts assets investments fair value company 's benefit plans unfunded except us commingled funds level million million december december respectively million million us shortterminvestment funds level december december respectively fair value johnson johnson common stock directly held plan assets million total plan assets december million total plan assets december level gains losses table sets forth summary changes fair value plans level assets years ended december december equity commingled insurance dollars millions debt instruments securities funds contracts assets total level balance december realized gains losses unrealized gains losses purchases sales issuances settlements net balance december realized gains losses unrealized gains losses purchases sales issuances settlements net transfers inout exchange rate changes balance december savings plan company voluntary k savings plans designed enhance existing retirement programs covering eligible employees company matches percentage employees contributions consistent provisions plan johnson johnson annual report heshe eligible total company matching contributions plans million million million respectively capital treasury stock changes treasury stock treasury stock amounts millions except treasury stock shares thousands shares amount balance january employee compensation stock option plans issuance common stock associated acquisition synthes inc repurchase common stock balance december employee compensation stock option plans repurchase common stock balance december employee compensation stock option plans repurchase common stock balance december includes repurchase common stock associated acquisition synthes inc aggregate shares common stock issued approximately shares end cash dividends paid per share compared dividends per share per share july company announced board directors approved share repurchase program authorizing company purchase billion company 's shares common stock december billion repurchased program share repurchases take place open market time time based market conditions repurchase program time limit may suspended periods discontinued time shares acquired available general corporate purposes company intends finance share repurchase program available cash accumulated comprehensive income components comprehensive income loss consist following total gain accumulated foreign loss currency gainloss employee benefit derivatives comprehensive dollars millions translation securities plans hedges income loss january net changes december net changes december net changes december amounts accumulated comprehensive income presented net related tax impact foreign currency translation adjusted income taxes relates permanent investments international subsidiaries additional details comprehensive income see consolidated statements comprehensive income details reclassifications accumulated comprehensive income johnson johnson annual report gainloss securities reclassifications released income expense net employee benefit plans reclassifications included net periodic benefit cost see note additional details gainloss derivatives hedges reclassifications earnings recorded account hedged transaction see note additional details international currency translation translation subsidiaries operating nonus dollar currencies company determined local currencies international subsidiaries functional currencies except highly inflationary economies defined compound cumulative rates inflation past three years substantial portion cash flows local currency consolidating international subsidiaries balance sheet currency effects recorded component accumulated comprehensive income equity account includes results translating certain balance sheet assets liabilities current exchange rates accounts historical rates except located highly inflationary economies translation balance sheet accounts highly inflationary economies reflected operating results rollforward changes foreign currency translation adjustments included note net currency transaction gains losses included income expense losses million million million respectively earnings per share following reconciliation basic net earnings per share diluted net earnings per share fiscal years ended december december december millions except per share amounts basic net earnings per share attributable johnson johnson average shares outstanding basic potential shares exercisable stock option plans less shares repurchased treasury stock method convertible debt shares accelerated share repurchase program adjusted average shares outstanding diluted diluted net earnings per share attributable johnson johnson diluted net earnings per share calculation included dilutive effect convertible debt offset related reduction interest expense million aftertax million years diluted earnings per share calculation included shares related stock options exercise price options less average market value company 's stock diluted net earnings per share excluded million shares related stock options exercise price options greater average market value would result antidilutive effect diluted earnings per share diluted earnings per share calculation fiscal years ended december december included dilutive effect million shares million shares respectively related accelerated share repurchase program associated acquisition synthes inc see note consolidated financial statements additional details rental expense lease commitments rentals space vehicles manufacturing equipment office data processing equipment operating leases approximately million million million respectively approximate minimum rental payments required operating leases initial remaining noncancelable lease terms excess one year december dollars millions total johnson johnson annual report commitments capital leases significant common stock stock option plans stock compensation agreements december company stockbased compensation plans shares outstanding contracts company 's stock option plan longterm incentive plan longterm incentive plan longterm incentive plan expired april options restricted shares granted subsequent date longterm incentive plan longterm incentive plan company may issue million shares common stock plus shares canceled expired forfeited issued longterm incentive plan subsequent april shares available future grants longterm incentive plan million end compensation cost charged income plans million million million respectively total income tax benefit recognized income statement sharebased compensation costs million million million respectively total unrecognized compensation cost million million million respectively weighted average period cost recognized years years years respectively sharebased compensation costs capitalized part inventory insignificant periods company settles employee benefit equity issuances treasury shares treasury shares replenished throughout year number shares used settle employee benefit equity issuances stock options stock options expire years date grant vest service periods range months years options granted average high low prices companys common stock new york stock exchange date grant fair value option award estimated date grant using blackscholes option valuation model uses assumptions noted following table expected volatility represents blended rate year daily historical average volatility rate week average implied volatility rate based atthemoney traded johnson johnson options life years historical data used determine expected life option riskfree rate based us treasury yield curve effect time grant average fair value options granted respectively fair value estimated based weighted average assumptions riskfree rate expected volatility expected life years dividend yield summary option activity plan december december december changes years ending dates presented johnson johnson annual report aggregate intrinsic weighted value shares thousands outstanding shares average exercise price dollars millions shares january options granted options exercised options canceledforfeited shares december options granted options exercised options canceledforfeited shares december options granted options exercised options canceledforfeited shares december total intrinsic value options exercised million million million respectively following table summarizes stock options outstanding exercisable december shares thousands outstanding exercisable average exercise average exercise exercise price range options average life price options price average contractual life remaining years stock options outstanding december december average life years average life years respectively stock options exercisable december december average price average price respectively restricted share units performance share units company grants restricted share units vest service periods range months years company also grants performance share units paid shares johnson johnson common stock end threeyear performance period whether performance share units vest amount vest tied completion service periods range months years achievement threeyear period three equallyweighted goals directly align help drive longterm total shareholder return sales adjusted operational earnings per share relative total shareholder return number shares actually earned end threeyear period vary based actual performance target number performance share units granted summary restricted share units performance share units activity plans december presented johnson johnson annual report outstanding restricted outstanding performance shares thousands share units share units shares january granted issued canceledforfeited shares december granted issued canceledforfeited shares december granted issued canceledforfeited shares december average fair value restricted share units granted respectively using fair market value date grant fair value restricted share units discounted dividends paid restricted share units vesting period fair value restricted share units issued million million million respectively weighted average fair value performance share units granted calculated using weighted average fair market value three component goals date grant fair values sales earnings per share goals performance share unit estimated date grant using fair market value shares time award discounted dividends paid performance share units vesting period fair value relative total shareholder return goal performance share unit estimated date grant using monte carlo valuation model fair value performance share units issued million due accelerated vesting accordance plan document performance share units vested segments business geographic areas sales customers dollars millions consumer united states international total pharmaceutical united states international total medical devices united states international total worldwide total johnson johnson annual report pretax profit identifiable assets dollars millions consumer pharmaceutical medical devices total less expense allocated segments general corporate worldwide total additions property depreciation plant equipment amortization dollars millions consumer pharmaceutical medical devices segments total general corporate worldwide total sales customers longlived assets dollars millions united states europe western hemisphere excluding us asiapacific africa segments total general corporate non longlived assets worldwide total see note description segments company operates export sales significant company one wholesaler distributing products three segments represented approximately total consolidated revenues company customer represented total revenues amounts allocated segments include interest income expense noncontrolling interests general corporate income expense includes currency related expense billion associated acquisition synthes inc general corporate includes cash cash equivalents marketable securities includes net litigation expense million comprised million million million medical devices pharmaceutical consumer segments respectively includes million inprocess research development expense comprised million million pharmaceutical medical devices segments respectively medical devices segment includes net gain million divestiture orthoclinical diagnostics business synthes integration costs million million expense cost associated depuy asrtm hip program includes additional year branded prescription drug fee million pharmaceutical segment includes million net litigation expense comprised million million medical devices pharmaceutical segments respectively includes million synthes integrationtransaction costs medical devices segment includes million inprocess research development expense comprised million million pharmaceutical medical devices segments respectively medical devices segment also johnson johnson annual report includes million expense cost associated depuy asrtm hip program includes million income related adjustments comprised million million consumer pharmaceutical segments respectively includes million net litigation expense comprised million million pharmaceutical medical devices segments respectively includes million inprocess research development expense comprised million million pharmaceutical medical devices segments respectively includes million synthes integrationtransaction costs medical devices segment includes million asset writedowns adjustments comprised million million million pharmaceutical consumer medical devices segments respectively medical devices segment also includes million expense cost associated depuy asr hip program longlived assets include property plant equipment net respectively intangible assets goodwill net respectively johnson johnson annual report selected quarterly financial data unaudited selected unaudited quarterly financial data years summarized second third fourth first second third fourth dollars millions except per share data first q uarter quarter quarter quarter quarter quarter quarter quarter segment sales customers consumer pharmaceutical medical devices total sales gross profit earnings provision taxes income net earnings attributable johnson johnson basic net earnings per share attributable johnson johnson diluted net earnings per share attributable johnson johnson first quarter includes synthes integration costs million aftertax million beforetax million tax benefit associated conor medsystems second quarter includes litigation expense million aftertax million beforetax synthes integration costs million aftertax million beforetax third quarter includes additional year branded prescription drug fee million tax litigation expense million aftertax million beforetax synthes integration costs million aftertax million beforetax million aftertax million beforetax costs associated depuy asrtm hip program additionally fiscal third quarter includes net gain billion aftertax billion beforetax divestiture orthoclinical diagnostics business fourth quarter includes litigation expense primarily related product liability patent litigation million aftertax million beforetax synthes integration costs million aftertax million beforetax million aftertax million beforetax impairment inprocess research development first quarter includes synthes integrationtransaction costs million aftertax million beforetax net litigation expense million aftertax million beforetax second quarter includes net litigation expense million aftertax million beforetax synthes integrationtransaction costs million aftertax million beforetax third quarter includes net litigation expense million aftertax million beforetax synthes integrationtransaction costs million aftertax million beforetax million aftertax million beforetax impairment inprocess research development fourth quarter includes net litigation expense million aftertax million beforetax synthes integrationtransaction costs million aftertax million beforetax million aftertax million beforetax impairment inprocess research development million aftertax million beforetax costs associated depuy asr hip program million tax benefit associated scios inc business combinations divestitures certain businesses acquired million cash million liabilities assumed acquisitions accounted using acquisition method accordingly results operations included financial statements respective dates acquisition acquisitions included covagen ag privatelyheld biopharmaceutical company specializing development multispecific protein therapeutics fynomab technology platform alios biopharma inc privatelyheld clinical stage biopharmaceutical company focused developing therapies viral diseases orsltm electrolyte readytodrink brand jagdale industries ltd excess purchase price estimated fair value tangible assets acquired amounted million assigned identifiable intangible assets residual recorded goodwill amount approximately million identified value iprd associated johnson johnson annual report acquisitions covagen ag alios biopharma inc value iprd calculated using cash flow projections discounted inherent risk projects iprd related acquisition alios biopharma inc alios million associated alios lead compound al orally administered antiviral therapy treatment infants respiratory syncytial virus rsv probability success factor used reflect inherent clinical regulatory risk discount rate applied iprd related acquisition covagen ag million associated covagens lead compound cova currently phase b study psoriasis holding potential treatment broad range inflammatory diseases including rheumatoid arthritis probability success factor used reflect inherent clinical regulatory risk discount rate applied certain businesses acquired million cash million liabilities assumed acquisitions accounted using acquisition method accordingly results operations included financial statements respective dates acquisition assumed liabilities primarily represent fair value contingent consideration may payable related acquisition aragon pharmaceuticals inc per terms agreement additional payments million may paid future based reaching predetermined milestones acquisitions included flexible stenting solutions inc leading developer innovative flexible peripheral arterial venous biliary stents shanghai elsker mother baby co ltd baby care company china aragon pharmaceuticals inc privatelyheld pharmaceutical discovery development company focused drugs treat hormonallydriven cancers excess purchase price estimated fair value tangible assets acquired amounted million assigned identifiable intangible assets residual recorded goodwill amount approximately million identified value iprd associated acquisitions aragon pharmaceuticals inc flexible stenting solutions inc iprd related acquisition aragon pharmaceuticals inc million associated aragons androgen receptor antagonist program treatment hormonallydriven cancers value iprd calculated using cash flow projections discounted inherent risk projects probability success factors ranging used reflect inherent clinical regulatory risk discount rate applied iprd related acquisition flexible stenting solutions inc million associated approval peripheral vascular indications including superficial femoral artery indication probability success factor used discount rate ranging applied certain businesses acquired million cash stock million liabilities assumed acquisitions accounted using acquisition method accordingly results operations included financial statements respective dates acquisition acquisitions included synthes inc global developer manufacturer orthopaedics devices guangzhou bioseal biotech co ltd developer biologic combinations addressing moderate severe hemostasis angiotech pharmaceuticals inc intellectual property know related quilltm knotless tissueclosure device corimmun gmbh developer phase ii treatment chf calibra medical inc developer unique wearable threeday insulin patch convenient discreet mealtime dosing people diabetes take multiple daily injections insulinspectrum vision llc full service distributor contact lenses serving russia facilities ukraine kazakhstan marketing authorizations trademarks patents extending zyrtec related market rights australia canada excess purchase price estimated fair value tangible assets acquired amounted million assigned identifiable intangible assets residual recorded goodwill amount approximately million identified value iprd associated acquisitions corimmun gmbh synthes inc iprd related acquisition synthes inc million associated orthopaedic devices iprd associated corimmun million related chf treatment iprd values calculated using cash flow projections discounted risk inherent projects synthes inc probability success factor discounted using rate corimmun probability success factor discounted using rate company recorded charge billion impairment inprocess research development associated corimmun fiscal second quarter company completed acquisition synthes inc global developer manufacturer orthopaedics devices purchase price billion cash stock net acquisition cost transaction billion based cash hand closing billion terms agreement share synthes inc common stock exchanged chf cash shares johnson johnson common stock based calculated exchange ratio exchange ratio calculated june based relevant exchange rate closing price johnson johnson common stock date total fair value consideration transferred billion acquisition completed june based relevant exchange rate closing price johnson johnson common stock date total fair value johnson johnson annual report consideration transferred billion janssen pharmaceutical company organized laws ireland whollyowned subsidiary johnson johnson used cash hand satisfy cash portion merger consideration stock portion merger consideration consisted shares johnson johnson common stock purchased janssen pharmaceutical two banks pursuant two accelerated share repurchase asr agreements dated june june janssen pharmaceutical purchased aggregate approximately million shares johnson johnson common stock initial purchase price billion asr agreements shares delivered janssen pharmaceutical june fiscal third quarter company settled remaining liabilities asr agreements billion cash recorded reduction equity addition company believes transactions asr agreement series related internal transactions consummated tax efficient manner accordance applicable law possible internal revenue service could assert one contrary positions challenge transactions tax perspective challenged amount total purchase price synthes shares could treated subject applicable us tax approximately statutory rate company plus interest following table summarizes consideration transferred acquire synthes inc valued acquisition date june dollars millions cash multiply chf shares synthes common stock outstanding exchange ratea common stock multiply shares synthes common stock outstanding jj stock priceb total fair value consideration transferred synthes common stock outstanding million shares acquisition date chfusd exchange rate b johnson johnson closing stock price new york stock exchange acquisition date per share company continues execute integration plans combine businesses sales organizations systems locations result company continue incur integration costs operating results synthes reported company 's financial statements beginning june total sales net earnings synthes fiscal year ended december million million respectively following table provides pro forma results operations fiscal year ended december synthes inc acquired beginning period presented pro forma results include effect divestitures certain purchase accounting adjustments estimated changes depreciation amortization expense acquired tangible intangible assets however pro forma results include anticipated cost savings effects integration synthes inc accordingly amounts necessarily indicative results acquisition occurred dates indicated may occur future unaudited pro forma consolidated results dollars millions except per share amounts net sales net earnings attributable johnson johnson diluted net earnings per share attributable johnson johnson company recorded acquisition related costs tax million million million respectively recorded income expense cost products sold connection synthes acquisition depuy orthopaedics inc agreed divest certain rights assets related trauma business biomet inc completed initial closing transaction fiscal second quarter including countries represented majority sales december transaction closed worldwide exception synthes inc acquisition supplemental pro forma information accordance us gaap standards related business combinations goodwill intangible assets johnson johnson annual report provided impact aforementioned acquisitions material effect companys results operations cash flows financial position company divestitures included orthoclinical diagnostics business carlyle group ky brand reckitt benckiser group plc us certain markets benecol brand raisio plc gains divestitures businesses approximately billion company completed divestiture orthoclinical diagnostics business carlyle group approximately billion company recorded pretax net gain approximately billion orthoclinical diagnostics ' results included company 's medical devices segment pretax profit december assets classified held sale relating orthoclinical diagnostics companies countries completely closed due local regulatory requirements million inventory classified prepaid expenses consolidated balance sheet million property plant equipment classified assets consolidated balance sheet company divestitures included women 's sanitary protection products us canada caribbean energizer holdings inc rolaids chattem inc doribax rights shionogi sale certain consumer brands certain pharmaceutical products gains divestitures businesses billion company divestitures included bystolic nebivolol ip rights forest laboratories inc trauma business depuy orthopaedics inc biomet inc therakos business affiliate gores capital partners iii lp sale certain consumer brands rhogam business gains divestitures businesses billion january definitive agreement announced divest us license rights nucynta tapentadol nucynta er tapentadol extendedrelease tablets nucynta tapentadol oral solution approximately billion transaction expected close fiscal second quarter subject customary closing conditions completion financing legal proceedings johnson johnson certain subsidiaries involved various lawsuits claims regarding product liability intellectual property commercial matters governmental investigations legal proceedings arise time time ordinary course business company records accruals contingencies probable liability incurred amount loss reasonably estimated december company determined liabilities associated certain litigation matters probable reasonably estimated company accrued matters continue monitor related legal issue adjust accruals might warranted based new information developments accordance asc litigation regulatory matters discussed loss probable reasonably possible company unable determine estimate possible loss range loss beyond amounts already accrued matters affected various factors including whether damages sought proceedings unsubstantiated indeterminate scientific legal discovery commenced complete proceedings early stages matters present legal uncertainties significant facts dispute numerous parties involved amounts accrued legal contingencies often result complex series judgments future events uncertainties rely heavily estimates assumptions company 's opinion based examination matters experience date discussions counsel ultimate outcome legal proceedings net liabilities accrued company 's balance sheet expected material adverse effect company 's financial position however resolution reporting period one matters either alone aggregate may material adverse effect company 's results operations cash flows period product liability certain subsidiaries johnson johnson involved numerous product liability claims lawsuits involving multiple products claimants cases seek substantial compensatory available punitive damages subsidiaries believe substantial defenses feasible predict ultimate outcome litigation company established product liability accruals compliance asc based currently available information cases may limited addition product liability accruals represent projected product liability thousands claims around world different litigation environments different fact patterns changes accruals may required future additional information becomes available significant cases include depuy asr xl acetabular system depuy asr hip resurfacing system pinnacle acetabular cup system pelvic meshes risperdal december us approximately plaintiffs direct claims pending lawsuits regarding injuries allegedly due asr xl acetabular system depuy asr hip resurfacing system respect pinnacle acetabular cup system respect pelvic meshes respect risperdal johnson johnson annual report august depuy orthopaedics inc depuy announced worldwide voluntary recall asr xl acetabular system depuy asr hip resurfacing system used hip replacement surgery claims personal injury made depuy johnson johnson number pending lawsuits expected fluctuate certain lawsuits settled dismissed additional lawsuits filed cases filed federal courts united states organized multidistrict litigation united states district court northern district ohio litigation also filed countries outside united states primarily united kingdom canada australia november depuy reached agreement courtappointed committee lawyers representing asr hip system plaintiffs establish program settle claims eligible asr hip patients united states surgery replace asr hips known revision surgery august settlement covered approximately patients february depuy reached additional agreement subject final documentation would effectively extend existing settlement program asr hip patients revision surgeries august prior february second agreement estimated cover approximately additional patients estimated cost agreements covered existing accruals settlement program expected bring close significant asr hip litigation activity us however many lawsuits us remain settlement program address litigation outside us company continues receive information respect potential costs associated recall worldwide basis company established accruals costs associated depuy asr hip program related product liability litigation updates accruals may required future additional information becomes available claims personal injury also made depuy johnson johnson relating depuy 's pinnacle acetabular cup system used hip replacement surgery number pending product liability lawsuits continues increase company continues receive information respect potential costs anticipated number cases cases filed federal courts united states organized multidistrict litigation united states district court northern district texas litigation also filed countries outside united states primarily united kingdom company established accrual cover defense costs connection product liability litigation associated depuy 's pinnacle acetabular cup system changes accrual may required future additional information becomes available claims personal injury made ethicon inc ethicon johnson johnson arising ethicon 's pelvic mesh devices used treat stress urinary incontinence pelvic organ prolapse number pending product liability lawsuits continues increase company continues receive information respect potential costs anticipated number cases cases filed federal courts united states organized multidistrict litigation united states district court southern district west virginia addition class actions individual personal injury cases claims commenced australia belgium canada england israel italy netherlands scotland venezuela seeking damages alleged injury resulting ethicon 's pelvic mesh devices company established accrual respect product liability litigation associated ethicon 's pelvic mesh products changes accrual may required future additional information becomes available claims personal injury made janssen pharmaceuticals inc johnson johnson arising use risperdal indicated treatment schizophrenia acute manic mixed episodes associated bipolar disorder irritability associated autism related compounds number pending product liability lawsuits continues increase company continues receive information respect potential costs anticipated number cases company established accrual cover defense costs connection product liability litigation associated risperdal changes accrual may required future additional information becomes available intellectual property certain subsidiaries johnson johnson subject time time legal proceedings claims related patent trademark intellectual property matters arising businesses many matters involve challenges coverage andor validity patents various products although subsidiaries believe substantial defenses challenges respect material patents assurance outcome matters loss cases could potentially adversely affect ability subsidiaries sell products require payment past damages future royalties significant matters described medical devices january tyco healthcare group lp tyco us surgical corporation covidien plc filed lawsuit ethicon endosurgery inc ees united states district court district connecticut alleging ees 's harmonic shears infringed three tyco patents case tried july march court ruled ees 's harmonic shears infringed tyco 's patents ordered ees pay damages approximately million declined order injunctive relief ees appealed december united states court appeals federal johnson johnson annual report circuit reversed district court 's ruling found asserted claims invalid january tyco filed motion rehearing july covidien filed another patent infringement lawsuit ees united states district court district connecticut seeking damages preliminary injunction alleging ees 's newest version harmonic scalpels harmonic ace shears harmonic ace shears infringed three tyco patents asserted previous case covidien brought motion preliminary injunction harmonic ace shears october district court granted covidien 's motion preliminary injunction ees appealed court appeals federal circuit granted ees interim stay injunction claims asserted covidien case claims declared invalid december court appeals tyco case discussed november roche diagnostics operations inc et al roche filed patent infringement lawsuit lifescan inc lifescan united states district court district delaware alleging lifescan 's onetouch line blood glucose monitoring systems infringe two patents related use microelectrode sensors roche seeking monetary damages injunctive relief september lifescan obtained favorable ruling claim construction precluded finding infringement court entered judgment roche july roche appealed court appeals reversed district court 's ruling claim construction remanded case district court new findings issue december district court ruled lifescan 's favor reinstated original claim construction february roche appealed ruling june rembrandt vision technologies lp rembrandt filed patent infringement lawsuit johnson johnson vision care inc jjvc united states district court eastern district texas alleging jjvc 's manufacture sale acuvueadvance acuvue oasys hydrogel contact lenses infringe us patent chang patent rembrandt seeking monetary relief case transferred united states district court middle district florida may jury returned verdict holding neither accused lenses infringes ' patent rembrandt appealed august united states court appeals federal circuit affirmed district court 's judgment rembrandt asked district court grant new trial based alleged new evidence july district court denied rembrandts motion rembrandt appealed district court 's denial motion new trial december state israel filed lawsuit district court tel aviv jaffa omrix biopharmaceuticals inc various affiliates omrix lawsuit state claims employee governmentowned hospital inventor several patents related fibrin glue technology employee developed government employee state claims right transfer intellectual property omrix belongs state state seeking damages plus royalties quixil evicel products alternatively transfer patents state case remains active trial date set september lifescan inc lifescan filed lawsuit shasta technologies instacare corp conductive technologies collectively shasta united states district court northern district california patent infringement making marketing strip use lifescan 's onetouch blood glucose meters shasta alleged three lifescan patentsinsuit invalid shasta also challenged validity asserted patents united states patent trademark office uspto patent infringement case stayed pending outcome uspto proceedings validity two patents confirmed uspto august uspto determined third patent us patent ' patent invalid lifescan appealing decision patent case resumed two patents april shasta brought counterclaims alleged antitrust violations false advertising claims stayed pending resolution patent infringement case may lifescan filed patent infringement lawsuit unistrip technologies llc unistrip united states district court district north carolina alleging making marketing unistrips strips infringe patents asserted shasta case stayed pending outcome appeal uspto 's decision validity ' patent july unistrip brought lawsuit lifescan united states district court eastern district pennsylvania alleging antitrust violations relating marketing practices lifescan 's strips november howmedica osteonics corp howmedica stryker ireland ltd stryker filed patent infringement lawsuit depuy orthopaedics inc depuy united states district court district new jersey alleging infringement depuy 's pinnacle acetabular cup system duraloc acetabular cup system patent relating duallocking mechanism feature acetabular cup system howmedica stryker sought monetary damages injunctive relief depuy filed counterclaim february asserting stryker 's trident acetabular hip system infringes depuy 's us patent depuy sought damages injunctive relief june case settled dismissed may medtronic minimed inc medtronic puerto rico operations co minimed distribution corp collectively medtronic minimed filed patent infringement lawsuit animas corporation animas united states district court central district california alleging animas 's onetouch ping glucose management system ir ir ir insulin pumps infringe nine patents medtronic minimed since withdrew two patents lawsuit seeking monetary damages injunctive relief respect remaining patents july animas entered settlement lawsuit johnson johnson annual report september bonutti skeletal innovations llc bonutti nonpracticing entity filed patent infringement lawsuit depuy mitek llc depuy institute llc depuy synthes institute llc depuy inc depuy synthes inc depuy orthopaedics inc collectively depuy united states district court district massachusetts alleging depuys manufacture sale andor method using sigma family partial total knee systems lcs complete knee system willfully infringe three bonuttis patents bonutti also alleges method using certain depuys suture anchors willfully infringe four bonuttis patents august parties entered settlement portion lawsuit relating suture anchors march medinol ltd medinol filed patent infringement lawsuit cordis corporation cordis johnson johnson united states district court southern district new york alleging cordis 's sales cypher cypher select stents made united states since willfully infringed four medinol 's patents directed geometry articulated stents medinol seeking damages attorney 's fees trial january district court dismissed case finding medinol unreasonably delayed bringing claims medinol appeal decision september district court denied motion medinol vacate judgment grant new trial medinol appealing decision january baxter international inc baxter healthcare corporation baxter healthcare sa collectively baxter filed lawsuit johnson johnson ethicon inc ethicon ferrosan medical devices packaging coordinators inc united states district court northern district illinois alleging manufacture importation sale andor use ethicons surgiflo hemostatic matrix family products infringes six baxters patents baxter seeking monetary damages injunctive relief february baxter also filed complaint united states international trade commission itc defendants alleging importation united states ethicons surgiflo hemostatic matrix family products violates section tariff act due alleged infringement four products seeking exclusion order enjoin importation united states products district court case stayed pending outcome itc case patents expire august itc case tried january parties awaiting decision june health inc health filed patent infringement lawsuit lifescan inc lifescan united states district court eastern district texas alleging lifescan 's onetouch verioiq blood glucose monitoring system infringes health 's patent related method monitoring treating patients health seeking monetary damages injunctive relief august lifescan filed motion dismiss lawsuit october lifescan filed inter partes review proceeding united states patent trademark office seeking invalidate healths patent december lifescan moved stay lawsuit pending decision inter partes review proceeding december bonutti skeletal innovations llc bonutti sued depuy synthes sales inc depuy synthes products inc united states district court district massachusetts alleging depuy synthes 's product line spine implants infringes six patents owned bonutti generally covering wedge implants methods implantation pharmaceutical may abbott biotechnology ltd abbott filed patent infringement lawsuit centocor inc centocor janssen biotech inc jbi united states district court district massachusetts alleging simponi infringes abbott 's us patent nos salfeld patents abbott seeking monetary damages injunctive relief parties settled case august abbott gmbh co abbott gmbh abbott bioresearch center collectively referred abbvie filed patent infringement lawsuit centocor jbi united states district court district massachusetts alleging stelara infringes two united states patents assigned abbott gmbh trial held september jury returned verdict favor jbi invalidating abbvie 's patent claims abbvie appealed july court appeals federal circuit affirmed lower court 's ruling also august abbott gmbh abbott laboratories limited collectively referred abbvie brought patent infringement lawsuit federal court canada alleging stelara infringes abbott gmbh 's canadian patent trial held december canadian case court ruled favor abbvie finding asserted claims valid infringed stelara jbi appealed decision may abbvie 's motion injunction granted part jbi also appealed decision october appellate court overturned finding liability remanded case trial court retrial lifted injunction addition us canadian litigations august abbvie filed patent infringement lawsuits related stelara netherlands switzerland germany parties settled cases discussed related stelara noramco inc noramco subsidiary johnson johnson moved intervene several patent infringement lawsuits filed united states district court southern district new york purdue pharma lp others purdue noramco oxycodone customers impax laboratories inc impax teva pharmaceuticals usa inc teva amneal pharmaceuticals llc amneal watson laboratories inc florida watson andrx labs llc johnson johnson annual report andrx lawsuits response defendants ' respective abbreviated new drug applications seeking approval market generic extended release oxycodone products expiration certain purdue patents three asserted patents relate oxycodone processes making oxycodone noramco agreed defend lawsuits behalf impax teva amneal watson andrx april watson andrx entered settlement purdue trial impax teva well two parties defended noramco took place september noramco defended teva impax november impax entered settlement purdue january court issued decision invalidating relevant purdue patents subsequently dismissed lawsuit amneal parties defended noramco purdue appealed court 's decision december teva entered confidential settlement purdue teva subsequently moved appeal dismissed moot view settlement purdue opposed teva 's motion august dr james swanson filed lawsuit alza corporation alza northern district california seeking added inventor three alzaowned patents relating concerta alternatively dr swanson alleged patentsinsuit invalid result alza 's alleged omission dr swanson named inventor lawsuit also includes claims fraud breach fiduciary duty unfair competition dr swanson seeking damages award unjust enrichment alza filed motion dismiss dr swanson 's claims well counterclaims breach contract negligent misrepresentation court granted motion part denied part alza filed motion summary judgment issue inventorship hearing held february parties awaiting decision johnson johnson acquired prostate cancer business aragon pharmaceuticals inc aragon including arn compound tested treatment prostate cancer september prior acquisition may medivation inc medivation sued aragon university california seeking rights arn december state court granted summary judgment aragon medivation 's claims awarding rights arn compound aragon january court dismissed case aragon medivation appealed remicade related cases march hospira healthcare corporation hospira filed impeachment proceeding kennedy institute rheumatology kennedy challenging validity canadian patent related remicade feldman patent exclusively licensed janssen biotech inc jbi october kennedy along jbi janssen inc cilag gmbh international affiliates jbi filed counterclaim infringement celltrion healthcare co ltd celltrion inc together celltrion hospira counterclaim alleges products described celltrions hospiras marketing applications health canada subsequent entry biologics seb remicade would infringe feldman patents owned kennedy discovery patent action ongoing trial scheduled september january health canada approved celltrions seb remicade allowing celltrion market biosimilar version remicade canada regardless pending patent action june hospira received approval seb remicade july janssen inc janssen filed lawsuit compel canadian minister health withdraw notice compliance hospiras seb hospira serve notice allegation janssen address patent listed janssen patent register notice compliance withdrawn hospira would serve notice allegation janssen could commence application prohibit issuance notice compliance expiry relevant patent hearing scheduled march september jbi nyu langone medical center nyu medical center received office action united states patent trademark office uspto rejecting claims us patent relating remicade ' patent reexamination proceeding instituted third party ' patent coowned jbi nyu medical center nyu medical center granted jbi exclusive license nyu medical center 's rights patent currently ' patent united states expires september jbi responded rejection december august jbi nyu medical center received rejection jbi responded rejection filing amendment november jbi 's petition enter amendment granted application returned examiner issuance new office action occurred february rejecting patent jbi sixty days respond rejection jbi believes ' patent valid respond latest office action defend patent necessary jbi pursue available appeals march celltrion filed declaratory judgment lawsuit jbi united states district court district massachusetts seeking invalidate ' patent two us patents relate remicade coowned jbi nyu medical center exclusively licensed jbi collectively le patents jbi moved dismiss case lack jurisdiction celltrion voluntarily dismissed lawsuit also march celltrion filed lawsuit united states district court southern district new york kennedy seeking invalidate three patents owned kennedy feldman patents feldman patents licensed jbi also relate remicade kennedy moved dismiss case lack jurisdiction including failure comply procedural requirements biologics price competition innovation act bpcia december court granted motion johnson johnson annual report august hospira inc hospira filed lawsuit united states district court southern district new york jbi new york university nyu nyu medical center kennedy seeking invalidate feldman patents hospira alleges exclusive rights market celltrion 's biosimilar version remicade united states approved fda october jbi nyu nyu medical center moved dismiss case lack jurisdiction including failure comply procedural requirements bpcia december court granted motion august celltrion filed fda approval make sell biosimilar version remicade february jbi received notice commercial marketing celltrion accordance bpcia notifying jbi celltrion andor hospira intend begin commercial marketing biosimilar product early days date notice parties proceeding patent resolution procedures set forth bpcia jbi believes patents valid enforce relevant patents le feldman patents found invalid patent could relied upon prevent introduction biosimilar versions remicade timing possible introduction biosimilar version remicade united states would subject approval fda loss exclusivity likely result reduction sales biosimilar versions remicade introduced market litigation filers abbreviated new drug applications andas following summarizes lawsuits pending generic companies filed abbreviated new drug applications andas fda undertaken similar regulatory processes outside united states seeking market generic forms products sold various subsidiaries johnson johnson prior expiration applicable patents covering products andas typically include allegations noninfringement invalidity unenforceability applicable patents event subsidiaries successful actions statutory month stays andas expire united states district court rulings obtained thirdparty companies involved ability upon approval fda introduce generic versions products issue market resulting potential substantial market share revenue losses products may result noncash impairment charge associated intangible asset prezista number generic companies filed andas seeking approval market generic versions prezista november tibotec inc tibotec llc tibotec pharmaceuticals janssen rd ireland collectively tibotec filed patent infringement lawsuit lupin ltd lupin pharmaceuticals inc collectively lupin mylan inc mylan pharmaceuticals inc collectively mylan united states district court district new jersey response lupin 's mylan 's respective andas seeking approval market generic versions tibotec 's prezista product expiration tibotec 's patent relating prezista lupin mylan filed counterclaims alleging noninfringement invalidity july tibotec filed another patent infringement lawsuit lupin united states district court district new jersey response lupin 's supplement anda add new dosage strengths proposed product august tibotec gd searle company gd searle filed patent infringement lawsuit lupin mylan response notice letters advising andas seeking approval market generic versions tibotec 's prezista product expiration two additional patents relating prezista tibotec exclusively licenses gd searle september court consolidated lawsuits referred first consolidated action approved new drug application prezista transferred tibotec inc janssen products lp december janssen products lp janssen rd ireland collectively janssen added several patents exclusively license gd searle first consolidated action mylan lupin june janssen gd searle dismissed claims relating patents owned gd searle lupin mylan based parties agreement seek fda approval respective andas november expiration gd searle patents trial regarding remaining patents first consolidated action court issued decision august favor janssen holding asserted patents valid would infringed lupin 's mylan 's marketing proposed products lupin filed appeal may lupin notified janssen filed anda seeking approval market new dosage strength generic version prezista response janssen filed patent infringement lawsuit united states district court district new jersey alleging lupin 's new dosage strength would infringe patents janssen asserting lupin original action march janssen filed patent infringement lawsuit lupin united states district court district new jersey alleging infringement united states patent january court consolidated lawsuits referred second consolidated action stayed pending lupin 's appeal court 's decision first consolidated action johnson johnson annual report janssen filed patent infringement lawsuit hetero drugs ltd unit iii hetero usa inc march united states district court district new jersey alleging infringement united states patent nos discovery case ongoing trial date set october janssen gd searle also filed patent infringement lawsuits teva pharmaceuticals usa inc teva pharmaceuticals ltd collectively teva united states district court district new jersey response teva 's anda seeking approval market generic version prezista expiration certain patents relating prezista janssen either owns exclusively licenses gd searle march parties entered settlement agreement lawsuits teva dismissed july janssen filed patent infringement lawsuit mylan united states district court district new jersey alleging infringement united states patent discovery case ongoing august janssen filed patent infringement lawsuits cipla ltd cipla usa inc collectively cipla united states district courts districts new jersey delaware response ciplas anda seeking approval market generic version janssens prezista product expiration certain janssens patents relating prezista cipla filed counterclaims seeking declarations noninfringement invalidity patentsinsuit discovery ongoing response notice allegation seeking approval market generic version prezista canada expiration canadian patent janssen inc janssen rd ireland filed notice application mylan pharmaceuticals ulc july december janssen rd ireland transferred prezista patents janssen sciences ireland uc janssen sciences ireland uc substituted janssen rd ireland plaintiff abovereferenced actions january janssen inc janssen sciences ireland uc filed notice application teva canada limited response notice allegation seeking approval market generic version prezista expiration canadian patent lawsuits janssen sought seeking order enjoining defendants marketing generic versions prezista expiration relevant patents concerta june alza corporation alza janssen pharmaceuticals inc jpi filed patent infringement lawsuits united states district court district delaware par pharmaceuticals inc par osmotica kereskedelmies szolgaltato kft osmotica norwich pharmaceuticals inc norwich response parties ' andas seeking approval market generic version concerta expiration united states patent ' patent addition september par osmotica filed counterclaims alza jpi seeking declarations invalidity noninfringement patentinsuit norwich filed motion dismiss norwich dismissed case october based agreement bound outcome case osmotica march alza jpi amended complaint par osmotica assert infringement newly issued united states patent patent june alza jpi osmotica entered settlement action september alza jpi par entered settlement may alza jpi filed patent infringement lawsuit united states district court district west virginia mylan inc mylan pharmaceuticals inc mylan response anda seeking approval market generic version concerta expiration patent mylan filed counterclaims seeking declarations invalidity noninfringement patentsinsuit june alza jpi filed patent infringement lawsuit district delaware sandoz inc response anda seeking approval market generic version concerta expiration patents sandoz filed counterclaims seeking declarations invalidity unenforceability noninfringement patentsinsuit december parties entered settlement agreement lawsuit dismissed december janssen inc alza filed notice application actavis pharma company actavis response notice allegation seeking approval market generic version concerta expiration canadian patent lawsuits alza andor jpi seeking order enjoining defendants marketing generic versions concerta expiration andor patents nucynta nucynta er july janssen pharmaceuticals inc jpi filed patent infringement lawsuits united states district court district new jersey actavis elizabeth llc actavis inc actavis llc collectively actavis well alkem laboratories limited ascend laboratories llc collectively alkem patent infringement claims actavis alkem relate respective andas seeking approval market generic version nucynta er expiration united states reissue patent patent united states patent patent actavis united states patent patent lawsuit also includes patent infringement claim johnson johnson annual report alkem response anda seeking approval market generic version nucynta expiration patents december jpi filed additional complaint district court new jersey alkem asserting united states patent related anda seeking approval market generic version nucynta er august jpi amended complaint alkem add additional dosage strengths october jpi received paragraph iv notice sandoz inc sandoz respect nucynta related patent paragraph iv notice roxane laboratories inc roxane respect nucynta related patents response notices jpi filed additional complaint united states district court district new jersey roxane sandoz asserting ' patent sandoz patents roxane april jpi sandoz entered joint stipulation dismissal case sandoz based sandozs agreement enter market prior expiration asserted patents june response paragraph iv notice roxane respect nucynta er jpi filed complaint asserting patents roxane july response paragraph iv notice watson laboratories inc watson respect nucynta oral solution product ' ' patents jpi filed lawsuit united states district court district new jersey asserting ' ' patents watson lawsuits jpi seeking order enjoining defendants marketing generic versions nucynta er nucynta expiration asserted patents government proceedings like companies pharmaceutical medical devices industries johnson johnson certain subsidiaries subject extensive regulation national state local government agencies united states countries operate result interaction government agencies ongoing significant litigation brought investigations conducted government agencies listed possible criminal charges substantial fines andor civil penalties damages could result government investigations litigation average wholesale price awp litigation johnson johnson several pharmaceutical subsidiaries jj awp defendants along numerous pharmaceutical companies defendants series lawsuits state federal courts involving allegations pricing marketing certain pharmaceutical products amounted fraudulent otherwise actionable conduct among things companies allegedly reported inflated average wholesale price awp drugs issue payors alleged used awps calculating provider reimbursement levels many cases federal actions state actions removed federal court consolidated pretrial purposes multidistrict litigation mdl united states district court district massachusetts plaintiffs cases included three classes private persons entities paid portion purchase drugs issue based awp state government entities made medicaid payments drugs issue based awp june trial merits mdl court dismissed claims two plaintiff classes jj awp defendants march court dismissed claims third class jj awp defendants without prejudice awp cases brought various attorneys general proceeded trial manufacturers several state cases certain subsidiaries johnson johnson settled including case alaska settled april cases still pending illinois new jersey wisconsin utah pennsylvania cases illinois new jersey wisconsin yet proceeded trial utah claims brought attorney general dismissed court state may appeal dismissal conclusion similar pending matters defendants awp case jj awp defendants brought attorney general commonwealth pennsylvania tried commonwealth court court found commonwealth 's favor regard certain claims pennsylvania unfair trade practices consumer protection law utpl entered injunction awarded million restitution million civil penalties court found jj awp defendants ' favor commonwealth 's claims unjust enrichment misrepresentationfraud civil conspiracy certain commonwealth 's claims utpl jj awp defendants appealed commonwealth court 's utpl ruling june pennsylvania supreme court vacated judgment entered commonwealth court remanded case proceedings remand january commonwealth court dismissed monetary awards jj awp defendants may appealed johnson johnson annual report risperdal november johnson johnson subsidiary janssen pharmaceuticals inc jpi finalized previously disclosed settlement agreements united states department justice fortyfive states resolving federal investigations state medicaid claims related past promotional practices risperdal matters jpi also settled alleged consumer fraud claims connection sale marketing risperdal thirtysix states district columbia september addition actions attorneys general several states brought actions jpi related sale marketing risperdal seeking one following remedies reimbursement medicaid public funds risperdal prescriptions written offlabel use compensation treating citizens alleged adverse reactions risperdal civil fines penalties violations state false claims acts consumer fraud statutes punitive damages relief relating alleged unfair business practices certain actions also sought injunctive relief relating promotion risperdal many actions claims brought state attorneys general settled either individually part settlements described four states remaining claims litigation related risperdal one claim remand arkansas case south carolina appeal kentucky trial set april mississippi case progressed trial company accrued amount equal judgment obtained south carolina extent state outstanding medicaidrelated claim resolved settlements referenced company accrued amount approximately equal state would received participated relevant federal settlement state cases went judgment trial discussed attorney general west virginia commenced lawsuit janssen pharmaceutica inc jpi based claims alleged consumer fraud duragesic well risperdal jpi found liable damages assessed million jpi filed appeal november west virginia supreme court appeals reversed trial court 's decision december attorney general west virginia dismissed case related risperdal without payment thereafter jpi settled case insofar related duragesic attorney general louisiana filed multicount complaint janssen pharmaceutica inc jpi johnson johnson later added defendant case tried october issue tried jury whether johnson johnson jpi violated state 's medical assistance program integrity law act misrepresentations allegedly made mailing november dear health care professional letter regarding risperdal jury returned verdict jpi johnson johnson violated act awarded million damages trial judge subsequently awarded attorney general counsel fees expenses amount million january louisiana supreme court reversed district courts judgment favor attorney general rendered judgment favor johnson johnson jpi april louisiana supreme court denied attorney general 's petition seeking rehearing appellate arguments resulting final dismissal case office general counsel commonwealth pennsylvania filed lawsuit janssen pharmaceutica inc jpi multicount complaint related janssen pharmaceutica 's sale risperdal commonwealth 's medicaid program trial occurred june trial judge dismissed case close plaintiff 's evidence commonwealth filed appeal july pennsylvania appeals court upheld dismissal commonwealth 's case attorney general south carolina filed lawsuit johnson johnson janssen pharmaceutica inc jpi several counts march matter tried jury liability time lawsuit limited claims violation south carolina unfair trade practices act including among others questions whether johnson johnson jpi engaged unfair deceptive acts practices conduct trade commerce distributing november dear health care professional letter regarding risperdal use product 's fdaapproved label jury found favor johnson johnson jpi june court awarded civil penalties approximately million jpi jpi appealed judgment company believes strong arguments supporting appeal oral argument appeal took place south carolina supreme court march parties awaiting decision april lawsuit brought attorney general arkansas jury found jpi johnson johnson court imposed penalties amount approximately billion january trial court awarded attorney fees approximately million jpi johnson johnson appealed awards arkansas supreme court march arkansas supreme court dismissed states claim arkansas medicaid fraud false claims act well approximately billion penalties reversed remanded claim arkansas deceptive trade practices act april arkansas supreme court rejected petition state rehearing case trial remand case scheduled june mcneil consumer healthcare starting june mcneil consumer healthcare division mcneilppc inc mcneil consumer healthcare certain affiliates including johnson johnson companies received grand jury subpoenas united states johnson johnson annual report attorney 's office eastern district pennsylvania requesting documents broadly relating recalls various products mcneil consumer healthcare fda inspections fort washington pennsylvania lancaster pennsylvania manufacturing facilities well certain documents relating recalls small number products subsidiaries addition february government served mcneilppc inc mcneilppc civil investigative demand seeking records relevant investigation determine violation federal false claims act grand jury false claims investigations continuing companies cooperating united states attorney 's office responding investigations companies also received civil investigative demands multiple state attorneys general offices broadly relating mcneil recall issues companies continue cooperate inquiries coordinated multistate coalition resolution reached multistate coalition possible individual state attorneys general offices may file civil monetary claims companies january oregon attorney general filed civil complaint johnson johnson mcneilppc mcneil healthcare llc state court alleging civil violations oregon unlawful trade practices act relating earlier recall mcneil otc product november state court granted motion companies dismiss oregon 's complaint entirety prejudice december oregon filed notice appeal court appeals state oregon oral argument took place july parties awaiting decision opioids litigation along pharmaceutical companies janssen pharmaceuticals inc jpi named number lawsuits alleging claims related opioid marketing practices may santa clara orange counties california counties filed complaint state court orange county california numerous pharmaceutical manufacturers including jpi alleging claims related opioid marketing practices including false advertising unfair competition public nuisance june city chicago filed complaint cook county circuit court several pharmaceutical manufacturers including jpi alleging number claims related opioid marketing practices including consumer fraud violations false claims case later removed united states district court northern district illinois december defendants filed motion dismiss city chicago 's first amended complaint failure state claim september tennessee attorney general division consumer affairs issued request information jpi related opioids marketing practices september synthes inc synthes received civil investigative demand issued pursuant false claims act united states attorney 's office eastern district pennsylvania demand sought information regarding allegations fellowships offered hospitals exchange agreements purchase products synthes produced documents information response demand cooperating inquiry may acclarent inc acclarent received subpoena united states attorney 's office district massachusetts requesting documents broadly relating sales marketing alleged offlabel promotion acclarent relieva stratus microflow spacer products investigation continuing acclarent cooperating united states attorney 's office responding subpoena august depuy orthopaedics inc depuy inc depuy synthes inc johnson johnson services inc companies received informal request united states attorney 's office district massachusetts civil division united states department justice united states production materials relating asr xl hip device july united states notified united states district court district massachusetts declined intervene qui tam case filed pursuant false claims act companies district court issued order august publicly unsealed united states ' declination notice however complaint matter remains seal addition october group state attorneys general issued civil investigative demands relating development sales marketing several depuy orthopaedics incs hip products july oregon department justice investigating matters independently states announced settlement asr xl hip device investigation total payment million state oregon october johnson johnson contacted california attorney general 's office regarding multistate attorney general investigation marketing surgical mesh products hernia urogynecological purposes johnson johnson 's subsidiary ethicon inc ethicon johnson johnson ethicon since entered series tolling agreements states district columbia participating multistate investigation responded civil investigative demands served certain participating states december therakos inc therakos formerly subsidiary johnson johnson part orthoclinical diagnostics inc ocd franchise received letter civil division united states attorney 's office eastern district pennsylvania informing therakos united states attorney 's office investigating sales marketing uvadex methoxsalen uvar xts system period present united states attorney 's johnson johnson annual report office requested ocd johnson johnson preserve documents could relate investigation therakos subsequently acquired affiliate gores capital partners iii lp january ocd johnson johnson retain certain liabilities may result investigation activity occurred prior sale therakos march united states attorneys office requested johnson johnson produce certain documents johnson johnson cooperating request following divestiture ocd johnson johnson retains ocds portion liability may result investigation activity occurred prior sale therakos may janssen pharmaceuticals inc jpi received subpoena atlanta regional office department health human services office inspector general seeking production documents information regarding sales marketing promotional practices including remuneration healthcare providers related nucynta ir nucynta er studies reports andor complaints regarding safety andor actual potential side effects nucynta ir nucynta er october united states department justice doj informed jpi government 's investigation stemmed filing qui tam complaint doj formally declined intervene qui tam action doj closing investigation related nucynta ir nucynta er plaintiff qui tam complaint filed notice dismissal court dismissed qui tam action december recent years johnson johnson received numerous requests variety united states congressional committees produce information relevant ongoing congressional inquiries policy johnson johnson cooperate inquiries producing requested information general litigation september johnson johnson filed lawsuit guidant corporation guidant united states district court southern district new york alleging guidant breached provisions merger agreement johnson johnson guidant june guidant filed motion summary judgment july judge denied guidants motion trial concluded january february decision issued court johnson johnson guidant entered settlement agreement pursuant guidant agreed pay johnson johnson million agreed sue johnson johnson affiliates patent infringement regarding certain stent products johnson johnson dismiss action guidant prejudice company record transaction fiscal year june following public announcement orthoclinical diagnostics inc ocd received grand jury subpoena united states department justice antitrust division connection investigation since closed multiple class action complaints filed ocd direct purchasers seeking damages alleged price fixing cases consolidated pretrial purposes united states district court eastern district pennsylvania blood reagent antitrust litigation august district court granted motion filed plaintiffs class certification october united states court appeals third circuit granted ocd 's petition interlocutory review class certification ruling oral argument appeal held february parties awaiting decision following divestiture ocd johnson johnson retains liability may result cases september shareholder ronald monk filed lawsuit united states district court district new jersey seeking class certification alleging johnson johnson certain individuals including executive officers employees johnson johnson failed disclose number manufacturing facilities failed maintain current good manufacturing practices result price company 's stock declined significantly plaintiff sought pursue remedies securities exchange act recover alleged economic losses december motion johnson johnson dismiss granted part denied part september plaintiff filed second amended complaint johnson johnson individual defendants moved dismiss plaintiff 's second amended complaint part following mediation parties reached agreement principle settle case july filed preliminary approval proposed settlement november court approved settlement three parties objected settlement appealed courts approval orders prior mediation appeal parties agreed dismiss appeal prejudice without costs party united states court appeals third circuit dismissed case april april omj pharmaceuticals inc omj pr filed lawsuit united states united states district court district puerto rico alleging overpayment federal income taxes tax years ended november november omj pr alleged internal revenue service erroneously calculated omj pr 's tax credits section tax code omj pr filed motion summary judgment united states filed cross motion summary judgment october court granted motion united states summary judgment denied motion omj pr summary judgment omj pr appealed decision june appellate court reversed trial courts decision instructed trial court enter summary judgment favor omj pr september johnson johnson johnson johnson inc mcneil consumer healthcare division johnson johnson inc received notice civil claim filed nick field supreme court british columbia canada bc johnson johnson annual report civil claim bc civil claim putative class action brought behalf persons reside british columbia purchased period september december one various mcneil infants ' children 's overthecounter medicines manufactured fort washington facility bc civil claim alleges defendants violated bc business practices consumer protection act canadian statutes common laws selling medicines allegedly safe andor effective comply canadian good manufacturing practices class certification hearing scheduled october august united states customs border protection issued penalty notice janssen ortho llc janssen ortho assessing penalties alleged improper classification darunavir ethanolate prezista connection importation united states october janssen ortho submitted petition relief response penalty notice johnson johnson subsidiaries also parties number proceedings brought comprehensive environmental response compensation liability act commonly known superfund comparable state local foreign laws primary relief sought cost past andor future remediation shareholder derivative action september two shareholder derivative lawsuits filed united states district court district new jersey donovan spamer george leon family trust naming current former directors johnson johnson defendants johnson johnson nominal defendant lawsuits allege defendants breached fiduciary duties decisions respect compensation chief executive officer period defendants made misleading statements company 's annual proxy statements lawsuits voluntarily dismissed without prejudice similar lawsuit george leon family trust v coleman refiled july lawsuit sought variety relief including monetary damages injunctive relief corporate governance reforms june board directors johnson johnson board received report prepared special independent counsel board investigated allegations contained derivative actions filed donovan spamer george leon family trust several shareholder demand letters board received raising similar issues report recommended johnson johnson reject shareholder demands take whatever steps necessary appropriate secure dismissal derivative litigation board unanimously adopted report 's recommendations september johnson johnson moved dismiss alternative summary judgment george leon family trust v coleman based upon boards determination october plaintiff leon litigation filed amended complaint johnson johnson moved dismiss amended complaint alternative summary judgment based upon boards determination june court granted summary judgment favor johnson johnson johnson johnson annual report report independent registered public accounting firm shareholders board directors johnson johnson opinion accompanying consolidated balance sheets related consolidated statements earnings statements comprehensive income statements equity statements cash flows present fairly material respects financial position johnson johnson subsidiaries december december results operations cash flows three years period ended december conformity accounting principles generally accepted united states america also opinion company maintained material respects effective internal control financial reporting december based criteria established internal control integrated framework issued committee sponsoring organizations treadway commission coso company 's management responsible financial statements maintaining effective internal control financial reporting assessment effectiveness internal control financial reporting included accompanying management 's report internal control financial reporting responsibility express opinions financial statements company 's internal control financial reporting based integrated audits conducted audits accordance standards public company accounting oversight board united states standards require plan perform audits obtain reasonable assurance whether financial statements free material misstatement whether effective internal control financial reporting maintained material respects audits financial statements included examining test basis evidence supporting amounts disclosures financial statements assessing accounting principles used significant estimates made management evaluating overall financial statement presentation audit internal control financial reporting included obtaining understanding internal control financial reporting assessing risk material weakness exists testing evaluating design operating effectiveness internal control based assessed risk audits also included performing procedures considered necessary circumstances believe audits provide reasonable basis opinions company 's internal control financial reporting process designed provide reasonable assurance regarding reliability financial reporting preparation financial statements external purposes accordance generally accepted accounting principles company 's internal control financial reporting includes policies procedures pertain maintenance records reasonable detail accurately fairly reflect transactions dispositions assets company ii provide reasonable assurance transactions recorded necessary permit preparation financial statements accordance generally accepted accounting principles receipts expenditures company made accordance authorizations management directors company iii provide reasonable assurance regarding prevention timely detection unauthorized acquisition use disposition company 's assets could material effect financial statements inherent limitations internal control financial reporting may prevent detect misstatements also projections evaluation effectiveness future periods subject risk controls may become inadequate changes conditions degree compliance policies procedures may deteriorate pricewaterhousecoopers llp pricewaterhousecoopers llp florham park new jersey february johnson johnson annual report managements report internal control financial reporting section sarbanesoxley act management required assess effectiveness companys internal control financial reporting end fiscal year report based assessment whether companys internal control financial reporting effective management company responsible establishing maintaining adequate internal control financial reporting companys internal control financial reporting designed provide reasonable assurance reliability companys financial reporting preparation external financial statements accordance generally accepted accounting principles internal controls financial reporting matter well designed inherent limitations therefore internal control financial reporting determined effective provide reasonable assurance respect financial statement preparation may prevent detect misstatements moreover projections evaluation effectiveness future periods subject risk controls may become inadequate changes conditions degree compliance policies procedures may deteriorate companys management assessed effectiveness companys internal control financial reporting december making assessment company used criteria established committee sponsoring organizations treadway commission coso internal controlintegrated framework criteria areas control environment risk assessment control activities information communication monitoring companys assessment included extensive documenting evaluating testing design operating effectiveness internal controls financial reporting based companys processes assessment described management concluded december companys internal control financial reporting effective effectiveness companys internal control financial reporting december audited pricewaterhousecoopers llp independent registered public accounting firm stated report appears herein alex gorsky dominic j caruso alex gorsky dominic j caruso chairman board directors vice president finance chief executive officer chief financial officer johnson johnson annual report summary operations statistical data dollars millions except per share amounts sales customers us sales customers international total sales cost products sold selling marketing administrative expenses research development expense inprocess research development interest income interest expense net portion capitalized income expense net restructuring earnings provision taxes income provision taxes income net earnings add net loss attributable noncontrolling interest net earnings attributable johnson johnson percent sales customers diluted net earnings per share common stock percent return average shareholders equity percent increase decrease previous year sales customers diluted net earnings per share supplementary balance sheet data property plant equipment net additions property plant equipment total assets longterm debt operating cash flow common stock information dividends paid per share shareholders equity per share market price per share yearend close average shares outstanding millions basic diluted employees thousands attributable johnson johnsonjohnson johnson annual report shareholder return performance graphs set forth line graphs comparing cumulative total shareholder return companys common stock periods five years ten years ending december cumulative total return standard poors stock index standard poors pharmaceutical index standard poors health care equipment index graphs tables assume invested december december companys common stock standard poors stock index standard poors pharmaceutical index standard poors health care equipment index dividends reinvested johnson johnson annual report johnson johnson annual report exhibit subsidiaries johnson johnson new jersey corporation us international subsidiaries shown december certain us subsidiaries international subsidiaries named significant aggregate johnson johnson subsidiary entity jurisdiction name subsidiary organization us subsidiaries acclarent inc delaware advanced sterilization products services inc new jersey alios biopharma inc delaware alza corporation delaware animas corporation delaware aragon pharmaceuticals inc delaware biosense webster inc california calibra medical inc delaware cna development llc delaware codman shurtleff inc new jersey cordis corporation florida cordis financing corporation delaware cordis llc delaware depuy mitek llc massachusetts depuy orthopaedics inc indiana depuy products inc indiana depuy spine llc ohio depuy synthes products inc delaware depuy synthes sales inc massachusetts depuy synthes inc delaware diabetes diagnostics inc delaware ethicon endosurgery inc ohio ethicon endosurgery llc delaware ethicon llc delaware ethicon us llc texas ethicon inc new jersey jj holdings nevada inc nevada janssen biotech inc pennsylvania janssen global services llc new jersey janssen oncology inc delaware janssen ortho llc delaware janssen pharmaceuticals inc pennsylvania janssen products lp new jersey janssen research development llc new jersey janssen scientific affairs llc new jersey janssen supply group llc pennsylvania janssencilag manufacturing llc delaware jjhc llc delaware jnj international investment llc delaware johnson johnson middle east inc new jersey johnson johnson consumer companies inc new jersey johnson johnson finance corporation new jerseyjohnson johnson health wellness solutions inc michigan johnson johnson health care systems inc new jersey johnson johnson innovation jjdc inc new jersey johnson johnson international new jersey johnson johnson japan inc new jersey johnson johnson sales logistics company llc new jerseyjurisdiction name subsidiary organization johnson johnson services inc new jersey johnson johnson urban renewal associates new jersey johnson johnson vision care inc florida jom pharmaceutical services inc delaware lifescan inc california mcneil consumer pharmaceuticals co new jersey mcneil healthcare llc delaware mcneil mmp llc new jersey mcneil nutritionals llc delaware mcneilppc inc new jersey mentor texas lp delaware mentor worldwide llc delaware micrus endovascular llc delaware middlesex assurance company limited vermont neutrogena corporation delaware noramco inc georgia omj pharmaceuticals inc delaware omrix biopharmaceuticals inc delaware ortho biologics llc delaware rutan realty llc new jersey sterilmed inc minnesota synthes usa products llc delaware synthes usa llc delaware synthes inc delaware international subsidiaries apsis france apsis germany gmbh germany beijing dabao cosmetics co ltd china berna biotech korea corporation korea republic berna rhein bv netherlands biosense webster israel ltd israel cilag advanced technologies gmbh switzerland cilag ag switzerland cilag gmbh international switzerland cilag holding ag switzerland cilag pharmaceuticals gmbh switzerland cilag products gmbh switzerland cordis de mexico sa de cv mexico cordis europa nv netherlands corimmun gmbh germany covagen ag switzerland crucell holland bv netherlands crucell nv netherlands crucell sweden ab sweden crucell switzerland ag switzerland depuy ireland ireland depuy france francejurisdiction name subsidiary organization depuy international holdings limited united kingdom depuy international limited united kingdom depuy motion sarl switzerland depuy synthes apollo limited ireland depuy synthes eos limited ireland depuy synthes gorgan limited ireland depuy synthes jason limited ireland depuy synthes leto sarl luxembourg depuy uk holdings limited united kingdom ees holdings de mexico de rl de cv mexico ees sa de cv mexico ethicon france ethicon ireland ireland ethicon pr holdings ireland ethicon women 's health urology sarl switzerland ethnor farmaceutica sa venezuela fms future medical system sa switzerland gmed healthcare bvba belgium jc general services cvba belgium janssen alzheimer immunotherapy holding limited ireland janssen biologics ireland ireland janssen biologics bv netherlands janssen cilag farmaceutica sa argentina janssen de mexico de rl de cv mexico janssen inc canada janssen infectious diseasesdiagnostics bvba belgium janssen korea ltd korea republic janssen pharmaceutica nv belgium janssen pharmaceutical ireland janssen pharmaceutical holdings ireland janssen pharmaceutical kk japan janssen rd ireland ireland janssen sciences ireland uc ireland janssencilag france janssencilag ab sweden janssencilag ag switzerland janssencilag bv netherlands janssencilag farmaceutica ltda brazil janssencilag farmaceutica lda portugal janssencilag gmbh germany janssencilag kft hungary janssen cilag limited thailand janssencilag limited united kingdom janssencilag nv belgium janssencilag oy finland janssencilag pharma gmbh austria janssencilag pharmaceutical saci greece janssencilag pty ltd australiajurisdiction name subsidiary organization janssencilag sa colombia janssencilag spa italy janssencilag ca venezuela janssencilag sa spain janssencilag sa de cv mexico jc health care ltd israel jjc acquisition company bv netherlands johnson johnson china investment ltd china johnson johnson china ltd china johnson johnson hong kong limited hong kong johnson johnson ireland limited ireland johnson johnson new zealand limited new zealand johnson johnson philippines inc philippines johnson johnson proprietary limited south africa johnson johnson thailand ltd thailand johnson johnson ab sweden johnson johnson ag switzerland johnson johnson consumer thailand limited thailand johnson johnson consumer bv netherlands johnson johnson consumer holdings france france johnson johnson consumer services eame ltd united kingdom johnson johnson de argentina sac e argentina johnson johnson de chile sa chile johnson johnson de colombia sa colombia johnson johnson de mexico sa de cv mexico johnson johnson de venezuela sa venezuela johnson johnson del ecuador sa ecuador johnson johnson del peru sa peru johnson johnson brasil industria e comercio de produtos para saude ltda brazil johnson johnson european treasury company ireland johnson johnson finance limited united kingdom johnson johnson financial services gmbh germany johnson johnson gesellschaft mbh austria johnson johnson gmbh germany johnson johnson group holdings gmbh germany johnson johnson hellas commercial industrial sa greece johnson johnson holding gmbh germany johnson johnson holdings kk japan johnson johnson inc canada johnson johnson industrial ltda brazil johnson johnson innovation limited united kingdom johnson johnson international financial services company ireland johnson johnson kk japan johnson johnson kft hungary johnson johnson korea selling distribution limited liability company korea republic johnson johnson korea ltd korea republic johnson johnson limitada portugal johnson johnson limited united kingdomjurisdiction name subsidiary organization johnson johnson llc russian federation johnson johnson luxembourg finance company sarl luxembourg johnson johnson management limited united kingdom johnson johnson medical china ltd china johnson johnson medical pty limited south africa johnson johnson medical shanghai ltd china johnson johnson medical suzhou ltd china johnson johnson medical bv netherlands johnson johnson medical gmbh germany johnson johnson medical korea limited korea republic johnson johnson medical limited united kingdom johnson johnson medical mexico sa de cv mexico johnson johnson medical nv belgium johnson johnson medical products gmbh austria johnson johnson medical pty ltd australia johnson johnson medical sa argentina johnson johnson medical spa italy johnson johnson medical scs venezuela johnson johnson medikal sanayi ticaret limited sirketi turkey johnson johnson middle east fzllc united arab emirates johnson johnson pacific pty limited australia johnson johnson poland sp z oo poland johnson johnson private limited india johnson johnson pte ltd singapore johnson johnson pty limited australia johnson johnson sante beaute france france johnson johnson spa italy johnson johnson sdn bhd malaysia johnson johnson sihhi malzeme sanayi ticaret limited sirketi turkey johnson johnson swiss finance company limited united kingdom johnson johnson taiwan ltd taiwan johnson johnson vision care ireland ireland johnson johnson prodaja medicinskih farmacevtskih izdelkov doo slovenia johnson johnson sa spain johnson johnson sa de cv mexico johnson johnson sro czech republic johnson johnson sro slovakia latam international investment company ireland latam properties holdings ireland lifescan france lifescan scotland limited united kingdom mcneil ab sweden mcneil gmbh co ohg germany mcneil healthcare uk limited united kingdom mcneil manufacturing pty ltd australia mcneil products limited united kingdom mcneil sweden ab sweden medos international sarl switzerlandjurisdiction name subsidiary organization medos sarl switzerland mentor medical systems bv netherlands mentor medical systems cv netherlands obtech medical sarl switzerland omj ireland ireland omj pr holdings ireland omrix biopharmaceuticals ltd israel pt johnson johnson indonesia indonesia shanghai elsker mother baby co ltd china shanghai johnson johnson pharmaceuticals ltd china spectrum vision limited liability company russian federation synthes canada ltd canada synthes suzhou medical co ltd china synthes australia pty ltd australia synthes colombia sas colombia synthes gmbh germany synthes gmbh switzerland synthes holding ag switzerland synthes limited united kingdom synthes lux finance srl luxembourg synthes luxembourg srl luxembourg synthes medical immobilien gmbh germany synthes produktions gmbh switzerland synthes tuttlingen gmbh germany tasmanian alkaloids pty ltd australia tibotecvirco comm va belgium turnbuckle investment company ireland vania expansion france xianjanssen pharmaceutical ltd chinaexhibit consent independent registered public accounting firm hereby consent incorporation reference registration statements form nos form nos johnson johnson report dated february relating financial statements effectiveness internal control financial reporting appears annual report shareholders incorporated annual report pricewaterhousecoopers llp pricewaterhousecoopers llp florham park new jersey february exhibit certification chief executive officer pursuant section sarbanesoxley act alex gorsky certify reviewed annual report fiscal year ended december report johnson johnson company based knowledge report contain untrue statement material fact omit state material fact necessary make statements made light circumstances statements made misleading respect period covered report based knowledge financial statements financial information included report fairly present material respects financial condition results operations cash flows company periods presented report companys certifying officers responsible establishing maintaining disclosure controls procedures defined exchange act rules ae de internal control financial reporting defined exchange act rules af df company designed disclosure controls procedures caused disclosure controls procedures designed supervision ensure material information relating company including consolidated subsidiaries made known us others within entities particularly period report prepared b designed internal control financial reporting caused internal control financial reporting designed supervision provide reasonable assurance regarding reliability financial reporting preparation financial statements external purposes accordance generally accepted accounting principles c evaluated effectiveness companys disclosure controls procedures presented report conclusions effectiveness disclosure controls procedures end period covered report based evaluation disclosed report change companys internal control financial reporting occurred companys recent fiscal quarter companys fourth fiscal quarter case annual report materially affected reasonably likely materially affect companys internal control financial reporting companys certifying officers disclosed based recent evaluation internal control financial reporting companys auditors audit committee companys board directors persons performing equivalent functions significant deficiencies material weaknesses design operation internal control financial reporting reasonably likely adversely affect companys ability record process summarize report financial information b fraud whether material involves management employees significant role companys internal control financial reporting alex gorsky alex gorsky chief executive officer date february exhibit b certification chief financial officer pursuant section sarbanesoxley act dominic j caruso certify reviewed annual report fiscal year ended december report johnson johnson company based knowledge report contain untrue statement material fact omit state material fact necessary make statements made light circumstances statements made misleading respect period covered report based knowledge financial statements financial information included report fairly present material respects financial condition results operations cash flows company periods presented report companys certifying officers responsible establishing maintaining disclosure controls procedures defined exchange act rules ae de internal control financial reporting defined exchange act rules af df company designed disclosure controls procedures caused disclosure controls procedures designed supervision ensure material information relating company including consolidated subsidiaries made known us others within entities particularly period report prepared b designed internal control financial reporting caused internal control financial reporting designed supervision provide reasonable assurance regarding reliability financial reporting preparation financial statements external purposes accordance generally accepted accounting principles c evaluated effectiveness companys disclosure controls procedures presented report conclusions effectiveness disclosure controls procedures end period covered report based evaluation disclosed report change companys internal control financial reporting occurred companys recent fiscal quarter companys fourth fiscal quarter case annual report materially affected reasonably likely materially affect companys internal control financial reporting companys certifying officers disclosed based recent evaluation internal control financial reporting companys auditors audit committee companys board directors persons performing equivalent functions significant deficiencies material weaknesses design operation internal control financial reporting reasonably likely adversely affect companys ability record process summarize report financial information b fraud whether material involves management employees significant role companys internal control financial reporting dominic j caruso dominic j caruso chief financial officer date february exhibit certification chief executive officer pursuant section sarbanesoxley act undersigned alex gorsky chief executive officer johnson johnson new jersey corporation company pursuant usc adopted pursuant section sarbanesoxley act hereby certifies best knowledge company 's annual report fiscal year ended december report fully complies requirements section securities exchange act information contained report fairly presents material respects financial condition results operations company alex gorsky alex gorsky chief executive officer dated february certification furnished sec report pursuant section sarbanesoxley act shall except extent required act deemed filed company purposes section securities exchange act amended otherwise subject liability sectionexhibit b certification chief financial officer pursuant section sarbanesoxley act undersigned dominic j caruso chief financial officer johnson johnson new jersey corporation company pursuant usc adopted pursuant section sarbanesoxley act hereby certifies best knowledge company 's annual report fiscal year ended december report fully complies requirements section securities exchange act information contained report fairly presents material respects financial condition results operations company dominic j caruso dominic j caruso chief financial officer dated february certification furnished sec report pursuant section sarbanesoxley act shall except extent required act deemed filed company purposes section securities exchange act amended otherwise subject liability sectionexhibit cautionary statement pursuant private securities litigation reform act safe harbor forwardlooking statements company may time time make certain forwardlooking statements publiclyreleased materials written oral forwardlooking statements relate strictly historical current facts reflect managements assumptions views plans objectives projections future forwardlooking statements may identified use words plans expects anticipates estimates words similar meaning conjunction among things discussions future operations financial performance companys strategy growth product development regulatory approvals market position expenditures forwardlooking statements based current beliefs expectations assumptions regarding future events statements therefore subject uncertainties risks changes difficult predict many outside company 's control investors realize underlying assumptions prove inaccurate known unknown risks uncertainties materialize actual results could vary materially companys expectations projections investors therefore cautioned place undue reliance forwardlooking statements furthermore company undertake update forwardlooking statements result new information future events developments important factors could cause companys actual results differ materially expressed implied companys forwardlooking statements follows economic factors including inflation fluctuations interest rates currency exchange rates potential effect fluctuations revenues expenses resulting margins competitive factors including technological advances achieved patents attained competitors well new products introduced competitors market share gains competitors ' branded products generic productsstore brands challenges companys patents competitors allegations companys products infringe patents third parties could potentially affect companys competitive position ability sell products question require payment past damages future royalties particular firms filed abbreviated new drug applications biosimilar biological product applications fda otherwise challenged coverage andor validity company 's patents seeking market generic biosimilar forms many companys key pharmaceutical products prior expiration applicable patents covering products event company successful defending resulting lawsuits generic biosimilar versions products issue introduced market resulting potential substantial market share revenue losses impact patent expirations company 's business operating results patents expire competitors may able legally produce market similar products technologies including biosimilars generics would material adverse effect company 's sales results operations significant changes customer relationships changes behavior spending patterns purchasers health care products services including delaying medical procedures rationing prescription medications reducing frequency physician visits foregoing health care insurance coverage impact international operations financial instability international economies sovereign risk possible imposition governmental controls restrictive economic policies unstable international governments legal systems health care changes us countries resulting pricing pressures including continued consolidation among health care providers trends toward managed care health care cost containment shift towards governments becoming primary payers health care expenses laws regulations relating sales promotion reimbursement access pricing generally government laws regulations affecting us international operations including relating taxes price controls regulatory approval new products licensing patent rights environmental protection conflict minerals possible drug reimportation legislation trade monetary fiscal policies securities laws compliance competition research internally externally sourced involving development improvement new existing products processes particularly significant results time time product process obsolescence development new improved products important companys success areas business investments development commercialization collaborations externally sourced innovation inherently risky guarantee success challenges difficulties inherent product development including potential inability successfully continue technological innovation complete clinical trials obtain regulatory approvals us internationally gain maintain market approval products possibility encountering infringement claims competitors respect patent intellectual property rights preclude delay commercialization product challenges involved postmarket surveillance activities studies data collection analysis real world context product efficacy safety concerns whether based scientific evidence resulting product withdrawals recalls regulatory action part fda international counterparts declining sales significant litigation government action adverse company including product liability claims patent infringement claims antitrust claims due uncertain nature litigation government action outcome one matter may result charges excess established accruals product liability insurance products may limited cost prohibitive unavailable increased scrutiny health care industry government agencies state attorneys general resulting investigations prosecutions carry risk significant civil criminal penalties including limited debarment government business failure meet compliance obligations mcneilppc inc consent decree corporate integrity agreements johnson johnson pharmaceutical affiliates depuy synthes companies compliance agreements governments government agencies could result significant sanctions difficulties delays manufacturing internally within supply chain cause voluntary involuntary business interruptions shutdowns product shortages substantial modifications business practices operations withdrawals suspensions current products market possible civil penalties criminal prosecution interruptions breaches computer communications systems including computer viruses hacking cyberattacks could impair company 's ability conduct business communicate internally customers result theft trade secrets misappropriation assets otherwise compromise privacy sensitive information belonging company customers business partners impact business combinations including acquisitions divestitures company well externally pharmaceutical medical devices consumer industries potential expected strategic benefits opportunities acquisition divestiture company may realized may take longer realize expected uncertainty commercial success new existing products ability company successfully execute strategic plans reliance global supply chains production distribution processes complex subject increasing regulatory requirements may adversely affect sourcing supply pricing materials used products may involve multiple third parties require significant capital expenditures subject lengthy regulatory approvals financial distress bankruptcies experienced significant customers suppliers could impair ability case may purchase companys products pay products previously purchased meet obligations company supply arrangements possibility us internal revenue service could assert one contrary positions challenge transactions consummated connection acquisition synthes inc tax perspective challenged amount total purchase price synthes shares could treated subject applicable us tax approximately statutory rate company plus interest changes global climate extreme weather natural disasters could affect demand company 's products services cause disruptions manufacturing distribution networks alter availability goods services within supply chain affect overall design integrity company 's products operations impact political economic conditions due terrorist attacks us parts world us military action overseas well instability financial markets could result terrorism military actions issuance new revised accounting standards financial accounting standards board securities exchange commission foregoing list sets forth many factors could impact upon companys ability achieve results described forwardlooking statements investors understand possible predict identify factors consider list complete statement potential risks uncertainties company identified factors list permitted private securities litigation reform act